<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Ther Adv Chronic Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">Ther Adv Chronic Dis</journal-id>
<journal-id journal-id-type="publisher-id">TAJ</journal-id>
<journal-id journal-id-type="hwp">sptaj</journal-id>
<journal-title-group>
<journal-title>Therapeutic Advances in Chronic Disease</journal-title>
</journal-title-group>
<issn pub-type="ppub">2040-6223</issn>
<issn pub-type="epub">2040-6231</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32215197</article-id>
<article-id pub-id-type="pmc">7065291</article-id>
<article-id pub-id-type="doi">10.1177/2040622320905215</article-id>
<article-id pub-id-type="publisher-id">10.1177_2040622320905215</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Retinal correlates of psychiatric disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Almonte</surname>
<given-names>Melanie T.</given-names>
</name>
<aff id="aff1-2040622320905215">Western Eye Hospital, Imperial College Healthcare NHS Trust (ICHNT), London, UK</aff>
<aff id="aff2-2040622320905215">Imperial College Ophthalmic Research Group (ICORG), Imperial College London, UK</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Capellàn</surname>
<given-names>Pamela</given-names>
</name>
<aff id="aff3-2040622320905215">Weill Cornell Medicine, New York, NY, USA</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yap</surname>
<given-names>Timothy E.</given-names>
</name>
<aff id="aff4-2040622320905215">Western Eye Hospital, Imperial College Healthcare NHS Trust (ICHNT), London, UK</aff>
<aff id="aff5-2040622320905215">Imperial College Ophthalmic Research Group (ICORG), Imperial College London, UK</aff>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-8663-6525</contrib-id>
<name>
<surname>Cordeiro</surname>
<given-names>Maria Francesca</given-names>
</name>
<xref ref-type="corresp" rid="corresp1-2040622320905215"></xref>
<aff id="aff6-2040622320905215">Glaucoma and Retinal Neurodegeneration Group, Department of Visual Neuroscience, UCL Institute of Ophthalmology 11-43 Bath Street, London EC1V 9EL, UK</aff>
<aff id="aff7-2040622320905215">Western Eye Hospital, Imperial College Healthcare NHS Trust (ICHNT), London, UK</aff>
<aff id="aff8-2040622320905215">Imperial College Ophthalmic Research Group (ICORG), Imperial College London, UK</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-2040622320905215">
<email>M.Cordeiro@ucl.ac.uk</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>9</day>
<month>3</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>11</volume>
<elocation-id>2040622320905215</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>9</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>8</day>
<month>1</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2020</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder>
<license license-type="creative-commons" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">
<license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Diagnosis and monitoring of psychiatric disorders rely heavily on subjective self-reports of clinical symptoms, which are complicated by the varying consistency of accounts reported by patients with an impaired mental state. Hence, more objective and quantifiable measures have been sought to provide clinicians with more robust methods to evaluate symptomology and track progression of disease in response to treatments. Owing to the shared origins of the retina and the brain, it has been suggested that changes in the retina may correlate with structural and functional changes in the brain. Vast improvements in retinal imaging, namely optical coherence tomography (OCT) and electrodiagnostic technology, have made it possible to investigate the eye at a microscopic level, allowing for the investigation of potential biomarkers <italic>in vivo</italic>. This review provides a summary of retinal biomarkers associated with schizophrenia, bipolar disorder and major depression, demonstrating how retinal biomarkers may be used to complement existing methods and provide structural markers of pathophysiological mechanisms that underpin brain dysfunction in psychiatric disorders.</p>
</abstract>
<kwd-group>
<kwd>retina</kwd>
<kwd>optical coherence tomography (OCT)</kwd>
<kwd>electroretinogram (ERG)</kwd>
<kwd>schizophrenia</kwd>
<kwd>bipolar disorder</kwd>
<kwd>major depression</kwd>
<kwd>biomarker</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January-December 2020</meta-value>
</custom-meta>
<custom-meta>
<meta-name>typesetter</meta-name>
<meta-value>ts1</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="section1-2040622320905215" sec-type="intro">
<title>Introduction</title>
<p>Mental disorders now comprise the leading cause of disability globally.<sup><xref ref-type="bibr" rid="bibr1-2040622320905215">1</xref></sup> They afflict people without discrimination of age, geography or income level,<sup><xref ref-type="bibr" rid="bibr2-2040622320905215">2</xref></sup> with an estimated one in three people affected by a mental illness during their lifetime.<sup><xref ref-type="bibr" rid="bibr3-2040622320905215">3</xref>,<xref ref-type="bibr" rid="bibr4-2040622320905215">4</xref></sup> Mental disorders are associated with a lower quality of life and significantly correlated with chronic disease (i.e. cardiovascular disease, diabetes) development.<sup><xref ref-type="bibr" rid="bibr5-2040622320905215">5</xref>,<xref ref-type="bibr" rid="bibr6-2040622320905215">6</xref></sup> The Diagnostic and Statistical Manual of Mental Disorders (DSM) introduced a standard and operationalised diagnostic framework within which to make psychiatric diagnoses. Although its initial intent was to increase reliability of diagnoses and ensure continuity of care, clinical diagnosis and monitoring of psychiatric disorders often remain dependent on patient reports of clinical symptoms.<sup><xref ref-type="bibr" rid="bibr7-2040622320905215">7</xref></sup> These subjective accounts may also be compromised if patients are in an impaired mental state.</p>
<p>In such cases, family member reports play an important role in clinical diagnosis, such as in the case of patients with Asperger syndrome and other autism spectrum disorders.<sup><xref ref-type="bibr" rid="bibr8-2040622320905215">8</xref></sup> Moreover, clinicians differ in the process of making diagnoses as recommended by diagnostic manuals,<sup><xref ref-type="bibr" rid="bibr9-2040622320905215">9</xref></sup> which could jeopardise the patient’s treatment and care. Clinically, the functional elements of the conditions are likely to remain the therapeutic focus; however, retinal biomarkers may be a useful adjunct in detecting or predicting any structural or functional progression of neuropsychiatric disease, although longitudinal studies are needed to validate if indeed psychiatric structural changes in the brain are reflected in the retina.</p>
<p>Diagnosing schizophrenia, bipolar disorder and major depression commonly involves screening scales and patient-reported outcome measures. For major depression disorder, the Patient Health Questionnaire (PHQ-9) is a commonly used tool for diagnosis,<sup><xref ref-type="bibr" rid="bibr10-2040622320905215">10</xref></sup> but has been found not to provide a strong index for severity of disease.<sup><xref ref-type="bibr" rid="bibr11-2040622320905215">11</xref></sup> According to a study by Kjaergaard and colleagues, other commonly used screening tools, such as the Beck Depression Inventory-II, the Montgomery and Åsberg Depression Rating Scale, were concluded to be useful for screening a major depression episode but not reliable in accurately diagnosing depression, hence necessitating the need for a comprehensive tool to guide and monitor treatment response.<sup><xref ref-type="bibr" rid="bibr12-2040622320905215">12</xref></sup> In one study observing the reliability of patient-reported outcome measures (PROMs) in schizophrenia, differences were found in PROM self-ratings provided consequently by patients with schizophrenia.<sup><xref ref-type="bibr" rid="bibr13-2040622320905215">13</xref></sup> Greater differences were associated with higher degrees of disorganisation and cognitive impairment, thus suggesting the lack of reliability in patient reports. It is important to note that symptoms of schizophrenia can change over time, thus making it challenging to use symptomology screening scales as the mainstay.<sup><xref ref-type="bibr" rid="bibr14-2040622320905215">14</xref></sup> Further to this, screening tools such as the Mood Disorder Questionnaire (MDQ) for bipolar disorder have been found to have a low positive predictive value, suggesting that such scales may not be reliable tools in clinical practice.<sup><xref ref-type="bibr" rid="bibr15-2040622320905215">15</xref></sup> Lastly, Svendsen and colleagues concluded that subjectively experienced cognitive function fails to predict objective function.<sup><xref ref-type="bibr" rid="bibr16-2040622320905215">16</xref></sup> Therefore, in order to gain a better understanding of the neurological changes that occur, objective measures must be sought. The gap in diagnostics and monitoring has called for more objective and quantifiable measures to equip clinicians with reliable tools to assess symptomology and to track disease progression in response to treatments.</p>
<p>The retina’s development from the same tissue as the brain, the neuroectoderm, suggests that retinal changes may parallel structural and functions changes in the brain.<sup><xref ref-type="bibr" rid="bibr17-2040622320905215">17</xref></sup> Noninvasive, retinal imaging technology, such as optical coherence tomography (OCT) and electrodiagnostics, have made it possible to determine potential biomarkers of neural tissue structure changes and disorder progression.<sup><xref ref-type="bibr" rid="bibr17-2040622320905215">17</xref></sup> OCT is a quick, noninvasive imaging device that captures cross-sectional retinal images down to the individual layers through high resolution using near-infrared light (<xref ref-type="fig" rid="fig1-2040622320905215">Figure 1</xref>).<sup><xref ref-type="bibr" rid="bibr18-2040622320905215">18</xref>,<xref ref-type="bibr" rid="bibr19-2040622320905215">19</xref></sup></p>
<fig id="fig1-2040622320905215" orientation="portrait" position="float">
<label>Figure 1.</label>
<caption>
<p>An SD-OCT cross-sectional macula scan of retinal layers.</p>
<p>BM, Bruch’s membrane; GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer; OPL, outer plexiform layer; PR-IS/OS, photoreceptor inner segment/outer segment; RNFL, retinal nerve fibre layer; RPE, retinal pigment epithelium; SD-OCT, spectral-domain optical coherence tomography.</p>
</caption>
<graphic xlink:href="10.1177_2040622320905215-fig1"></graphic>
</fig>
<p>With its power to achieve high resolution imaging, SD-OCT has allowed for a number of previously unseen changes to be assessed, such as reductions in retinal nerve fibre layer thickness in patients with schizophrenia and decreased choroidal thickness in patients with psychosis compared with healthy controls.<sup><xref ref-type="bibr" rid="bibr20-2040622320905215">20</xref>,<xref ref-type="bibr" rid="bibr21-2040622320905215">21</xref></sup> Oberwahrenbrock and colleagues investigated the inter-rater reliability of semiautomated segmentation of OCT scans across five centres in the United States and Europe, and concluded that OCT scans are highly reliable in a neurodegenerative population. Thus, OCT scans can potentially serve as a reliable tool in clinical trials assessing retinal injury in psychiatric disorders.<sup><xref ref-type="bibr" rid="bibr22-2040622320905215">22</xref></sup> Thus, retinal imaging allows for the possibility of surrogate biomarkers to guide clinicians and researchers and provide greater insight on diseases that have historically relied on subjective self-reports and contradictory screening scales.</p>
<p>Determining biomarkers may provide researchers with an opportunity to reduce cost and time in clinical trials and allow clinicians to diagnose earlier, monitor disorder progression and guide treatment. The studies in this review examine the correlation between retinal markers and disease presence, severity and duration in schizophrenia, bipolar disorder and major depression. The aims of this review are to demonstrate how retinal biomarkers may be utilised to enhance current clinical diagnostic methods and to discuss how changes in OCT measures may serve as surrogate markers of pathophysiological mechanisms that contribute to brain abnormalities in psychiatric disorders.</p>
</sec>
<sec id="section2-2040622320905215">
<title>Schizophrenia</title>
<p>Schizophrenia is a chronic, debilitating psychiatric disorder that affects an estimated 4.0 per 1000 people over a lifetime,<sup><xref ref-type="bibr" rid="bibr23-2040622320905215">23</xref></sup> and is ranked the fifth leading cause of disability worldwide in 15- to 44-year olds.<sup><xref ref-type="bibr" rid="bibr24-2040622320905215">24</xref></sup> Diagnosis is complex and relies primarily on clinical judgement of positive symptoms (e.g. hallucinations, delusions, disorganised speech) or negative symptoms (e.g. avolition, flat affect).<sup><xref ref-type="bibr" rid="bibr25-2040622320905215">25</xref>,<xref ref-type="bibr" rid="bibr26-2040622320905215">26</xref></sup> Symptoms may also fluctuate over time, with several other conditions acting as possible mimics including infectious,<sup><xref ref-type="bibr" rid="bibr14-2040622320905215">14</xref></sup> neurological, metabolic and other psychological disorders.<sup><xref ref-type="bibr" rid="bibr27-2040622320905215">27</xref><xref ref-type="bibr" rid="bibr28-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr29-2040622320905215">29</xref></sup> These factors make diagnosing schizophrenia challenging.</p>
<p>Diminished total brain volume seen on MRI is a well-established characteristic of schizophrenia.<sup><xref ref-type="bibr" rid="bibr30-2040622320905215">30</xref></sup> In a large (352 studies) meta-analysis collating cross-sectional volume indices, longer illness duration and high doses of antipsychotics were negatively correlated with grey matter volume. Similarly, with severity of disease, grey matter volumes of the superior temporal gyrus and gyrus rectus have been found to correlate negatively with the positive scales of the Positive and Negative Syndrome Scale (PANSS), and superior temporal gyrus and anterior cingulate cortex correlated negatively with negative scales.<sup><xref ref-type="bibr" rid="bibr31-2040622320905215">31</xref></sup></p>
<p>There is evidence that early identification and treatment of psychotic symptoms markedly improves clinical outcomes.<sup><xref ref-type="bibr" rid="bibr32-2040622320905215">32</xref>,<xref ref-type="bibr" rid="bibr33-2040622320905215">33</xref></sup> Given the weak predictive value of clinical features, diagnoses based on objective biomarkers would be of paramount value.<sup><xref ref-type="bibr" rid="bibr26-2040622320905215">26</xref>,<xref ref-type="bibr" rid="bibr34-2040622320905215">34</xref></sup> Visual impairments, including deficits in visual acuity and contrast sensitivity,<sup><xref ref-type="bibr" rid="bibr35-2040622320905215">35</xref>,<xref ref-type="bibr" rid="bibr36-2040622320905215">36</xref></sup> are both common and have a high sensitivity for converting to psychosis compared with other symptoms.<sup><xref ref-type="bibr" rid="bibr37-2040622320905215">37</xref></sup> Visual impairments have been associated with psychosis from the prodromal phase,<sup><xref ref-type="bibr" rid="bibr38-2040622320905215">38</xref></sup> to first episodes,<sup><xref ref-type="bibr" rid="bibr39-2040622320905215">39</xref><xref ref-type="bibr" rid="bibr40-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr41-2040622320905215">41</xref></sup> in addition to higher rates of psychosis,<sup><xref ref-type="bibr" rid="bibr42-2040622320905215">42</xref>,<xref ref-type="bibr" rid="bibr43-2040622320905215">43</xref></sup> increased severity of illness and chronicity.<sup><xref ref-type="bibr" rid="bibr42-2040622320905215">42</xref>,<xref ref-type="bibr" rid="bibr44-2040622320905215">44</xref><xref ref-type="bibr" rid="bibr45-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr46-2040622320905215">46</xref></sup> Visual deficits may also be secondary to reduced access to healthcare in that patients’ deficits may stem from underutilising healthcare services regardless of visual changes.<sup><xref ref-type="bibr" rid="bibr47-2040622320905215">47</xref></sup> It is uncertain to what extent visual impairments derive from the retina <italic>versus</italic> the brain. It has been suggested that structural and functional retinal changes may indicate progressive brain tissue loss in addition to explaining clinical features and perceptual visual processing deficits,<sup><xref ref-type="bibr" rid="bibr17-2040622320905215">17</xref></sup> as established in multiple sclerosis and Alzheimer’s disease (AD).<sup><xref ref-type="bibr" rid="bibr48-2040622320905215">48</xref><xref ref-type="bibr" rid="bibr49-2040622320905215"></xref><xref ref-type="bibr" rid="bibr50-2040622320905215"></xref><xref ref-type="bibr" rid="bibr51-2040622320905215"></xref><xref ref-type="bibr" rid="bibr52-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr53-2040622320905215">53</xref></sup></p>
<sec id="section3-2040622320905215">
<title>Retinal neurotransmitters in schizophrenia</title>
<p>N-methyl-<sc>D</sc>-aspartate (NMDA) glutamatergic receptor hypoactivity and hyperactivity, also referred to as the glutamate hypothesis of schizophrenia, has been linked to the pathogenesis of both negative and positive symptoms in addition to neural excitotoxicity,<sup><xref ref-type="bibr" rid="bibr54-2040622320905215">54</xref><xref ref-type="bibr" rid="bibr55-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr56-2040622320905215">56</xref></sup> which can induce neurodegeneration.<sup><xref ref-type="bibr" rid="bibr57-2040622320905215">57</xref><xref ref-type="bibr" rid="bibr58-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr59-2040622320905215">59</xref></sup> Additionally, the same receptors mediate glutamatergic cone photoreceptor-bipolar cell pathways at the fovea.<sup><xref ref-type="bibr" rid="bibr60-2040622320905215">60</xref></sup> Photoreceptor complex thinning may represent NMDA dysfunction<sup><xref ref-type="bibr" rid="bibr54-2040622320905215">54</xref></sup>; however, there is no direct evidence to affirm that a glutamate surplus directly causes structural changes to the retina.<sup><xref ref-type="bibr" rid="bibr61-2040622320905215">61</xref>,<xref ref-type="bibr" rid="bibr62-2040622320905215">62</xref></sup> The dopamine hypothesis of schizophrenia proposes that dopamine abnormalities in the mesolimbic and mesocortical pathways contribute to the positive and negative symptoms of schizophrenia.<sup><xref ref-type="bibr" rid="bibr63-2040622320905215">63</xref>,<xref ref-type="bibr" rid="bibr64-2040622320905215">64</xref></sup> In the retina, dopamine is synthesised and released from amacrine cells (ACs) and is involved in several aspects of visual function including modulating visual acuity and contrast sensitivity.<sup><xref ref-type="bibr" rid="bibr65-2040622320905215">65</xref></sup> Reduced retinal dopamine has led to excessively strong coupling of ACs and horizontal cells (HCs), associated with increased inhibition, reduced contrast sensitivity and poorer visual acuity as a possible consequence.<sup><xref ref-type="bibr" rid="bibr66-2040622320905215">66</xref></sup></p>
</sec>
<sec id="section4-2040622320905215">
<title>Electroretinogram changes in schizophrenia</title>
<p>Changes in retinal function over time, or how they compare to healthy controls, can serve as an important biomarker for monitoring disease progression. Electroretinogram (ERG) assesses retinal function by measuring electrical activity of neuronal populations in response to light exposure.<sup><xref ref-type="bibr" rid="bibr46-2040622320905215">46</xref>,<xref ref-type="bibr" rid="bibr67-2040622320905215">67</xref></sup> In schizophrenia, abnormal ERG findings are well established, and have been reported in several recent studies.<sup><xref ref-type="bibr" rid="bibr68-2040622320905215">68</xref><xref ref-type="bibr" rid="bibr69-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr70-2040622320905215">70</xref></sup> Using portable hand-held flash ERG (fERG), Demmin and colleagues reported diminished a-wave and b-wave amplitude and latency in both photopic (light-adapted) and scotopic (dark adapted) conditions, suggesting weakened photoreceptor and bipolar cell activity.<sup><xref ref-type="bibr" rid="bibr68-2040622320905215">68</xref></sup> In contrast, Moghimi and colleagues saw a trend of decreasing b-wave amplitude in schizophrenia patients and healthy controls with regards to a-wave and latency, despite observing a trend towards reduced b-wave amplitude.<sup><xref ref-type="bibr" rid="bibr69-2040622320905215">69</xref></sup> Looking at the findings from a longitudinal standpoint, Hébert reported that cone a-wave and rod b-wave amplitude reductions seen in childhood were present in adults with schizophrenia.<sup><xref ref-type="bibr" rid="bibr71-2040622320905215">71</xref></sup> Finally, in a large study comparing medicated and stable 150 schizophrenia patients with 151 bipolar patients, both patient groups exhibited diminished cone a-wave amplitude and extended b-wave latency, whereas only schizophrenia patients exhibited diminished cone b-wave amplitude. Furthermore, bipolar and schizophrenia patients could be differentiated with 80% sensitivity and 82% specificity.<sup><xref ref-type="bibr" rid="bibr70-2040622320905215">70</xref></sup> These studies suggest ERG could be useful to clinicians in a number of ways, including making differential diagnoses and objectively tracking neurodevelopment of the condition and use and effectiveness of antipsychotic medications.</p>
</sec>
<sec id="section5-2040622320905215">
<title>OCT in schizophrenia</title>
<p>The use of OCT in schizophrenia is fairly novel, yet studies have revealed common themes, most notably retinal thinning and reduced macular thickness and macular volume (MV). Global retinal thinning has been reported in several studies.<sup><xref ref-type="bibr" rid="bibr61-2040622320905215">61</xref>,<xref ref-type="bibr" rid="bibr62-2040622320905215">62</xref>,<xref ref-type="bibr" rid="bibr72-2040622320905215">72</xref><xref ref-type="bibr" rid="bibr73-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr74-2040622320905215">74</xref></sup> Specifically, peripapillary RNFL thinning has been observed in the nasal, inferior and, predominately, in the superior quadrants (<xref ref-type="fig" rid="fig2-2040622320905215">Figure 2</xref>).<sup><xref ref-type="bibr" rid="bibr74-2040622320905215">74</xref><xref ref-type="bibr" rid="bibr75-2040622320905215"></xref><xref ref-type="bibr" rid="bibr76-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr77-2040622320905215">77</xref></sup> In contrast, Silverstein and colleagues reported no difference in RNFL thickness between schizophrenia patients and controls,<sup><xref ref-type="bibr" rid="bibr78-2040622320905215">78</xref></sup> and Ascaso and colleagues found these significant differences only amongst right eyes, the clinical relevance of which remains unclear (<xref ref-type="table" rid="table1-2040622320905215">Table 1</xref>). Macular thinning and reduced MV are another reported, yet debated, finding in patients with schizophrenia compared with age-matched controls. Whereas several studies observed overall macular thinning in patients compared with age-matched controls,<sup><xref ref-type="bibr" rid="bibr61-2040622320905215">61</xref>,<xref ref-type="bibr" rid="bibr62-2040622320905215">62</xref>,<xref ref-type="bibr" rid="bibr75-2040622320905215">75</xref>,<xref ref-type="bibr" rid="bibr79-2040622320905215">79</xref>,<xref ref-type="bibr" rid="bibr80-2040622320905215">80</xref></sup> one study observed macular thinning isolated to the nasal and inferior outer macular regions.<sup><xref ref-type="bibr" rid="bibr81-2040622320905215">81</xref></sup> In contrast, Silverstein and colleagues reported no difference in macular thinning between schizophrenia patients and age-matched controls.<sup><xref ref-type="bibr" rid="bibr78-2040622320905215">78</xref></sup> Additionally, Chu and colleagues observed no macular thinning in schizophrenia and schizoaffective patients compared with healthy controls. However, it is unclear how the results were affected by the inclusion of schizoaffective disorder, given that the majority of studies excluding schizoaffective patients report significant macular thinning.<sup><xref ref-type="bibr" rid="bibr82-2040622320905215">82</xref></sup></p>
<fig id="fig2-2040622320905215" orientation="portrait" position="float">
<label>Figure 2.</label>
<caption>
<p>Comparison of SD-OCT pRNFL thicknesses of the right eyes in a patient with schizophrenia (a) and a healthy patient (b). Yellow sectors indicate borderline limits.</p>
<p>pRNFL, peripapillary RNFL; RNFL, retinal nerve fibre layer; SD-OCT, spectral-domain optical coherence tomography.</p>
</caption>
<graphic xlink:href="10.1177_2040622320905215-fig2"></graphic>
</fig>
<table-wrap id="table1-2040622320905215" orientation="portrait" position="float">
<label>Table 1.</label>
<caption>
<p>A summary of studies reporting sector analysis of peripapillary RNFL changes in schizophrenia, bipolar disorder and major depression. Effect size has been calculated as mean percentage reduction in disease <italic>versus</italic> healthy controls.</p>
</caption>
<alternatives>
<graphic xlink:href="10.1177_2040622320905215-table1"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Schizophrenia<hr/></th>
<th align="left" colspan="1" rowspan="1">OCT type</th>
<th align="left" colspan="1" rowspan="1">Global</th>
<th align="left" colspan="2" rowspan="1">Superior<hr/></th>
<th align="left" colspan="1" rowspan="1">Temporal</th>
<th align="left" colspan="2" rowspan="1">Inferior<hr/></th>
<th align="left" colspan="1" rowspan="1">Nasal</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">
<italic>Study</italic>
</th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">ST</th>
<th align="left" colspan="1" rowspan="1">SN</th>
<th colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">IT</th>
<th align="left" colspan="1" rowspan="1">IN</th>
<th colspan="1" rowspan="1"></th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Ascaso<sup><xref ref-type="bibr" rid="bibr80-2040622320905215">80</xref></sup></td>
<td colspan="1" rowspan="1">TD</td>
<td colspan="1" rowspan="1">7.8%</td>
<td colspan="2" rowspan="1">6.3%</td>
<td colspan="1" rowspan="1">7.9%</td>
<td colspan="2" rowspan="1">9.4%</td>
<td colspan="1" rowspan="1">10.7%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Ascaso<sup><xref ref-type="bibr" rid="bibr75-2040622320905215">75</xref></sup></td>
<td colspan="1" rowspan="1">SD</td>
<td colspan="1" rowspan="1">9.8%<sup><xref ref-type="table-fn" rid="table-fn3-2040622320905215">b</xref></sup></td>
<td colspan="2" rowspan="1">10.7%<sup><xref ref-type="table-fn" rid="table-fn3-2040622320905215">b</xref></sup></td>
<td colspan="1" rowspan="1">5.8%</td>
<td colspan="2" rowspan="1">9.2%</td>
<td colspan="1" rowspan="1">15.5%<sup><xref ref-type="table-fn" rid="table-fn3-2040622320905215">b</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Celik<sup><xref ref-type="bibr" rid="bibr72-2040622320905215">72</xref></sup></td>
<td colspan="1" rowspan="1">SD</td>
<td colspan="1" rowspan="1">4.8%</td>
<td colspan="1" rowspan="1">5.1%</td>
<td colspan="1" rowspan="1">2.3%</td>
<td colspan="1" rowspan="1">4.7%</td>
<td colspan="1" rowspan="1">10.1%</td>
<td colspan="1" rowspan="1">6.7%</td>
<td colspan="1" rowspan="1">4.9%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Chu<sup><xref ref-type="bibr" rid="bibr82-2040622320905215">82</xref><xref ref-type="table-fn" rid="table-fn2-2040622320905215">a</xref></sup></td>
<td colspan="1" rowspan="1">TD</td>
<td colspan="1" rowspan="1">1.0%</td>
<td colspan="2" rowspan="1">0.9%</td>
<td colspan="1" rowspan="1">0.9%</td>
<td colspan="2" rowspan="1">−0.8%</td>
<td colspan="1" rowspan="1">−0.1%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Lee<sup><xref ref-type="bibr" rid="bibr62-2040622320905215">62</xref></sup></td>
<td colspan="1" rowspan="1">SD</td>
<td colspan="1" rowspan="1">8.9%</td>
<td colspan="2" rowspan="1">11.7%</td>
<td colspan="1" rowspan="1">9.9%</td>
<td colspan="2" rowspan="1">7.4%</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Topcu-Yilmaz<sup><xref ref-type="bibr" rid="bibr79-2040622320905215">79</xref></sup></td>
<td colspan="1" rowspan="1">SD</td>
<td colspan="1" rowspan="1">0.0%</td>
<td colspan="1" rowspan="1">0.8%</td>
<td colspan="1" rowspan="1">−2.2%</td>
<td colspan="1" rowspan="1">1.4%</td>
<td colspan="1" rowspan="1">2.3%</td>
<td colspan="1" rowspan="1">−1.4%</td>
<td colspan="1" rowspan="1">−1.2%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Yilmaz<sup><xref ref-type="bibr" rid="bibr81-2040622320905215">81</xref></sup></td>
<td colspan="1" rowspan="1">SD</td>
<td colspan="1" rowspan="1">5.9%</td>
<td colspan="2" rowspan="1">1.7%</td>
<td colspan="1" rowspan="1">3.5%</td>
<td colspan="2" rowspan="1">3.8%</td>
<td colspan="1" rowspan="1">7.9%</td>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">Bipolar disorder<hr/></th>
<th align="left" colspan="1" rowspan="1">OCT type</th>
<th align="left" colspan="1" rowspan="1">Global</th>
<th align="left" colspan="2" rowspan="1">Superior<hr/></th>
<th align="left" colspan="1" rowspan="1">Temporal</th>
<th align="left" colspan="2" rowspan="1">Inferior<hr/></th>
<th align="left" colspan="1" rowspan="1">Nasal</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">
<italic>Study</italic>
</th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">ST</th>
<th align="left" colspan="1" rowspan="1">SN</th>
<th colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">IT</th>
<th align="left" colspan="1" rowspan="1">IN</th>
<th colspan="1" rowspan="1"></th>
</tr>
<tr>
<td colspan="1" rowspan="1">Mehraban<sup><xref ref-type="bibr" rid="bibr83-2040622320905215">83</xref></sup></td>
<td colspan="1" rowspan="1">SD</td>
<td colspan="1" rowspan="1">6.8%</td>
<td colspan="2" rowspan="1">4.8%</td>
<td colspan="1" rowspan="1">−1.3%</td>
<td colspan="2" rowspan="1">8.0%</td>
<td colspan="1" rowspan="1">10.5%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Kalenderoglu<sup><xref ref-type="bibr" rid="bibr84-2040622320905215">84</xref></sup></td>
<td colspan="1" rowspan="1">SD</td>
<td colspan="1" rowspan="1">5.9%</td>
<td colspan="1" rowspan="1">3.9%</td>
<td colspan="1" rowspan="1">5.3%</td>
<td colspan="1" rowspan="1">−0.1%</td>
<td colspan="1" rowspan="1">3.5%</td>
<td colspan="1" rowspan="1">7.8%</td>
<td colspan="1" rowspan="1">3.1%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Khalil<sup><xref ref-type="bibr" rid="bibr85-2040622320905215">85</xref></sup></td>
<td colspan="1" rowspan="1">SD</td>
<td colspan="1" rowspan="1">14.8%</td>
<td colspan="2" rowspan="1">11.3%</td>
<td colspan="1" rowspan="1">7.4%</td>
<td colspan="2" rowspan="1">9.3%</td>
<td colspan="1" rowspan="1">3.6%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Polo<sup><xref ref-type="bibr" rid="bibr86-2040622320905215">86</xref></sup></td>
<td colspan="1" rowspan="1">SS</td>
<td colspan="1" rowspan="1">8.1%</td>
<td colspan="1" rowspan="1">16.5%</td>
<td colspan="1" rowspan="1">11.2%</td>
<td colspan="1" rowspan="1">4.3%</td>
<td colspan="1" rowspan="1">9.4%</td>
<td colspan="1" rowspan="1">4.7%</td>
<td colspan="1" rowspan="1">4.9%</td>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">Major depression<hr/></th>
<th align="left" colspan="1" rowspan="1">OCT type</th>
<th align="left" colspan="1" rowspan="1">Global</th>
<th align="left" colspan="2" rowspan="1">Superior<hr/></th>
<th align="left" colspan="1" rowspan="1">Temporal</th>
<th align="left" colspan="2" rowspan="1">Inferior<hr/></th>
<th align="left" colspan="1" rowspan="1">Nasal</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">
<italic>Study</italic>
</th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">ST</th>
<th align="left" colspan="1" rowspan="1">SN</th>
<th colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">IT</th>
<th align="left" colspan="1" rowspan="1">IN</th>
<th colspan="1" rowspan="1"></th>
</tr>
<tr>
<td colspan="1" rowspan="1">Yildiz<sup><xref ref-type="bibr" rid="bibr87-2040622320905215">87</xref></sup></td>
<td colspan="1" rowspan="1">SD</td>
<td colspan="1" rowspan="1">−0.1%</td>
<td colspan="2" rowspan="1">0.1%</td>
<td colspan="1" rowspan="1">4.2%</td>
<td colspan="2" rowspan="1">–0.4%</td>
<td colspan="1" rowspan="1">−5.4%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Sönmez<sup><xref ref-type="bibr" rid="bibr88-2040622320905215">88</xref><xref ref-type="table-fn" rid="table-fn3-2040622320905215">a</xref></sup></td>
<td colspan="1" rowspan="1">SD</td>
<td colspan="1" rowspan="1">1.7%</td>
<td colspan="1" rowspan="1">1.2%</td>
<td colspan="1" rowspan="1">−0.9%</td>
<td colspan="1" rowspan="1">0.2%</td>
<td colspan="1" rowspan="1">−0.1%</td>
<td colspan="1" rowspan="1">2.6%</td>
<td colspan="1" rowspan="1">4.6%</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="table-fn1-2040622320905215">
<p>Grey shading indicates statistical significance as chosen by each study investigator.</p>
</fn>
<fn id="table-fn2-2040622320905215">
<label>a</label>
<p>Mean of right and left eyes.</p>
</fn>
<fn id="table-fn3-2040622320905215">
<label>b</label>
<p>OD significant only.</p>
</fn>
<fn id="table-fn4-2040622320905215">
<p>IN, inferonasal; IT, inferotemporal; OCT, optical coherence tomography; RNFL, retinal nerve fibre layer; SD, spectral domain, SN, superonasal; ST, superotemporal; TD, time domain.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>On examination of the individual layers of the macula with OCT, one comprehensive study by Samani and colleagues found that total retinal thickness was significantly reduced in the foveal, nasal parafoveal, and temporal parafoveal regions, with all three zones having outer nuclear layer (ONL) and inner segment layer (ISL) thinning in common.<sup><xref ref-type="bibr" rid="bibr61-2040622320905215">61</xref></sup> Furthermore, thinning was observed to affect the parafoveal ganglion cell layer (GCL) temporally, and the inner plexiform layer (IPL) and retinal nerve fibre layer (RNFL) nasally.<sup><xref ref-type="bibr" rid="bibr61-2040622320905215">61</xref></sup> Of relevance to treatment potential in schizophrenia, lower macular volumes have been observed in treatment-refractory patients compared with treatment-responsive patients, possibly reflecting the duration of disease, but also with potential as a prognostic biomarker.<sup><xref ref-type="bibr" rid="bibr72-2040622320905215">72</xref></sup> In contrast, other studies have observed no difference in global mRNFL or choroidal thickness in schizophrenia and schizoaffective disorder when compared with healthy controls (<xref ref-type="table" rid="table2-2040622320905215">Table 2</xref>).<sup><xref ref-type="bibr" rid="bibr79-2040622320905215">79</xref>,<xref ref-type="bibr" rid="bibr82-2040622320905215">82</xref></sup> These contrasting findings have been attributed to small sample sizes, varying illness duration and lack of OCT resolution to detect loss of unmyelinated axons in early disease. In the latter study, Chu and colleagues found specifically that the right nasal RNFL in schizoaffective patients was significantly thinner (<italic>p</italic> = 0.02) compared with schizophrenia patients<sup><xref ref-type="bibr" rid="bibr82-2040622320905215">82</xref></sup>; however, the clinical relevance of this finding, if any, would need to be proven with further studies.</p>
<table-wrap id="table2-2040622320905215" orientation="portrait" position="float">
<label>Table 2.</label>
<caption>
<p>Structural retinal characteristics of patients diagnosed with schizophrenia, BD and depression.</p>
</caption>
<alternatives>
<graphic xlink:href="10.1177_2040622320905215-table2"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Schizophrenia<hr/></th>
<th align="left" colspan="1" rowspan="1">n</th>
<th align="left" colspan="1" rowspan="1">Mean age, years (SD)</th>
<th align="left" colspan="1" rowspan="1">Mean illness duration, years (SD)</th>
<th align="left" colspan="1" rowspan="1">Anti-psychotic medication status</th>
<th align="left" colspan="1" rowspan="1">Global RNFL thinning</th>
<th align="left" colspan="1" rowspan="1">Global Macular thinning</th>
<th align="left" colspan="1" rowspan="1">Choroidal thinning</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">
<italic>Study</italic>
</th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Ascaso<sup><xref ref-type="bibr" rid="bibr80-2040622320905215">80</xref></sup></td>
<td colspan="1" rowspan="1">20<sup><xref ref-type="table-fn" rid="table-fn6-2040622320905215">a</xref></sup></td>
<td colspan="1" rowspan="1">39.2 (13.5)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Ascaso<sup><xref ref-type="bibr" rid="bibr75-2040622320905215">75</xref></sup></td>
<td colspan="1" rowspan="1">37</td>
<td colspan="1" rowspan="1">45.1 (10.4)</td>
<td colspan="1" rowspan="1">16.3 (11.2)</td>
<td colspan="1" rowspan="1">Medicated</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Celik<sup><xref ref-type="bibr" rid="bibr72-2040622320905215">72</xref></sup></td>
<td colspan="1" rowspan="1">81</td>
<td colspan="1" rowspan="1">35.6 (10.2)</td>
<td colspan="1" rowspan="1">13.3 (9.1)</td>
<td colspan="1" rowspan="1">Medicated</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Chu<sup><xref ref-type="bibr" rid="bibr82-2040622320905215">82</xref></sup></td>
<td colspan="1" rowspan="1">49</td>
<td colspan="1" rowspan="1">29.9 (8.7)</td>
<td colspan="1" rowspan="1">4.4 (3.6)</td>
<td colspan="1" rowspan="1">Medicated and unmedicated</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Lee<sup><xref ref-type="bibr" rid="bibr62-2040622320905215">62</xref></sup></td>
<td colspan="1" rowspan="1">30</td>
<td colspan="1" rowspan="1">37.2 (10.7)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Medicated</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Samani<sup><xref ref-type="bibr" rid="bibr61-2040622320905215">61</xref></sup></td>
<td colspan="1" rowspan="1">35</td>
<td colspan="1" rowspan="1">40.6 (12.9)</td>
<td colspan="1" rowspan="1">16.3 (9.1)</td>
<td colspan="1" rowspan="1">Medicated</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Topcu-Yilmaz<sup><xref ref-type="bibr" rid="bibr79-2040622320905215">79</xref></sup></td>
<td colspan="1" rowspan="1">22</td>
<td colspan="1" rowspan="1">34.6 (9.5)</td>
<td colspan="1" rowspan="1">10.3<sup><xref ref-type="table-fn" rid="table-fn7-2040622320905215">b</xref></sup></td>
<td colspan="1" rowspan="1">Medicated and unmedicated</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Yilmaz<sup><xref ref-type="bibr" rid="bibr81-2040622320905215">81</xref></sup></td>
<td colspan="1" rowspan="1">68<sup><xref ref-type="table-fn" rid="table-fn6-2040622320905215">a</xref></sup></td>
<td colspan="1" rowspan="1">39.9 (10.3)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">Bipolar disorder<hr/></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">
<italic>Study</italic>
</th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
</tr>
<tr>
<td colspan="1" rowspan="1">Mehraban<sup><xref ref-type="bibr" rid="bibr83-2040622320905215">83</xref></sup></td>
<td colspan="1" rowspan="1">60<sup><xref ref-type="table-fn" rid="table-fn6-2040622320905215">a</xref></sup></td>
<td colspan="1" rowspan="1">33.8 (9.2)</td>
<td colspan="1" rowspan="1">10.6 (8.6)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Kalenderoglu<sup><xref ref-type="bibr" rid="bibr84-2040622320905215">84</xref></sup></td>
<td colspan="1" rowspan="1">43</td>
<td colspan="1" rowspan="1">35.6 (10.5)</td>
<td colspan="1" rowspan="1">6.8 (10.6)</td>
<td colspan="1" rowspan="1">Medicated and unmedicated</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Khalil<sup><xref ref-type="bibr" rid="bibr85-2040622320905215">85</xref></sup></td>
<td colspan="1" rowspan="1">40</td>
<td colspan="1" rowspan="1">30.9 (9.3)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Medicated</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Polo<sup><xref ref-type="bibr" rid="bibr86-2040622320905215">86</xref></sup></td>
<td colspan="1" rowspan="1">23<sup><xref ref-type="table-fn" rid="table-fn6-2040622320905215">a</xref></sup></td>
<td colspan="1" rowspan="1">49.7 (8.75)</td>
<td colspan="1" rowspan="1">16.2 (6.7)</td>
<td colspan="1" rowspan="1">Medicated and unmedicated</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">−</td>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">Major depression<hr/></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">
<italic>Study</italic>
</th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
</tr>
<tr>
<td colspan="1" rowspan="1">Yildiz<sup><xref ref-type="bibr" rid="bibr87-2040622320905215">87</xref></sup></td>
<td colspan="1" rowspan="1">58</td>
<td colspan="1" rowspan="1">44.6 (13.1)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Medicated and unmedicated</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Sönmez<sup><xref ref-type="bibr" rid="bibr88-2040622320905215">88</xref></sup></td>
<td colspan="1" rowspan="1">30</td>
<td colspan="1" rowspan="1">34.6 (8.8)</td>
<td colspan="1" rowspan="1">5.7 (7.3)</td>
<td colspan="1" rowspan="1">Medicated</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="table-fn5-2040622320905215">
<p>Positive (+) sign denotes statistically significant thinning compared with healthy controls. Negative (−) sign refers to no difference in thickness between those with disease and healthy controls. ‘n’ refers to number of patients.</p>
</fn>
<fn id="table-fn6-2040622320905215">
<label>a</label>
<p>Eyes.</p>
</fn>
<fn id="table-fn7-2040622320905215">
<label>b</label>
<p>Not reported.</p>
</fn>
<fn id="table-fn8-2040622320905215">
<p>RNFL, retinal nerve fibre layer; SD, standard deviation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section6-2040622320905215">
<title>Wide retinal venules in schizophrenia</title>
<p>There is growing evidence that people with schizophrenia have higher rates of cardiovascular disease (CVD),<sup><xref ref-type="bibr" rid="bibr9-2040622320905215">9</xref>,<xref ref-type="bibr" rid="bibr89-2040622320905215">89</xref><xref ref-type="bibr" rid="bibr90-2040622320905215"></xref><xref ref-type="bibr" rid="bibr91-2040622320905215"></xref><xref ref-type="bibr" rid="bibr92-2040622320905215"></xref><xref ref-type="bibr" rid="bibr93-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr94-2040622320905215">94</xref></sup> and the calibre of retinal microvasculature assessed through colour fundus photography is increasingly recognised as an important biomarker of subclinical CVD. Indeed, metabolic syndrome (MetS) has been well studied in schizophrenia.<sup><xref ref-type="bibr" rid="bibr95-2040622320905215">95</xref>,<xref ref-type="bibr" rid="bibr96-2040622320905215">96</xref></sup> MetS prevalence ranges from 5.6% in untreated schizophrenia inpatients in Brazil up to 74% in Hispanic outpatients.<sup><xref ref-type="bibr" rid="bibr97-2040622320905215">97</xref>,<xref ref-type="bibr" rid="bibr98-2040622320905215">98</xref></sup> Patients with schizophrenia are already at elevated risk of morbidity and mortality due to CVD, so given that antipsychotic medications may potentiate the damage, especially at young ages,<sup><xref ref-type="bibr" rid="bibr99-2040622320905215">99</xref>,<xref ref-type="bibr" rid="bibr100-2040622320905215">100</xref></sup> it is important to be able to monitor and anticipate cardiovascular changes to allay further injury from CVD.</p>
<p>Several familial studies have examined the association between schizophrenia or psychosis and retinal venule calibre with positive associations. The Dunedin Longitudinal Study, a birth cohort originally consisting of 1037 children, described how patients who developed schizophrenia by age 38 had distinctly wider retinal venules compared with healthy cohort members.<sup><xref ref-type="bibr" rid="bibr101-2040622320905215">101</xref></sup> Similarly, in the Twins Eye Study in Tasmania and the Brisbane Longitudinal Twin Study, individuals who experienced psychosis had wider venules compared with unaffected co-twins and controls; however, unaffected co-twins also exhibited wide venules compared with controls.<sup><xref ref-type="bibr" rid="bibr102-2040622320905215">102</xref></sup> These findings suggest widened retinal venules may reflect familial vulnerability to psychosis. Accordingly, genetic variants associated with both retinal vascular abnormalities and schizophrenia were described in the Dunedin study and revealed a strong genetic correlation between arterial diameter and weak correlation in venular diameter with a schizophrenia diagnosis.<sup><xref ref-type="bibr" rid="bibr103-2040622320905215">103</xref></sup> More recently, in a study examining the relationship between adult vascular-ischemia and the neurodevelopmental hypothesis, Moises, Wollschläger and Binder described an overwhelming number of schizophrenia-associated genes also involved with vascular function, regulation and repair.<sup><xref ref-type="bibr" rid="bibr104-2040622320905215">104</xref></sup> These findings suggest that vascular abnormalities evidenced by widened retinal venules may reflect a genotypic vulnerability to psychosis.</p>
</sec>
<sec id="section7-2040622320905215">
<title>Magnocellular pathway dysfunction in schizophrenia</title>
<p>Beginning in the M-ganglion cells of the retina, the magnocellular pathway branches out into the M-layers of the lateral geniculate nucleus (LGN) of the thalamus then into the dorsal stream and visual cortex located in the parietal lobe.<sup><xref ref-type="bibr" rid="bibr105-2040622320905215">105</xref></sup> Visual pathway deficits in schizophrenia are thought to stem from disturbances in this pathway, as evidenced by reduced visual field sensitivity,<sup><xref ref-type="bibr" rid="bibr106-2040622320905215">106</xref><xref ref-type="bibr" rid="bibr107-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr108-2040622320905215">108</xref></sup> eye-tracking,<sup><xref ref-type="bibr" rid="bibr109-2040622320905215">109</xref>,<xref ref-type="bibr" rid="bibr110-2040622320905215">110</xref></sup> motion-contrast sensitivity,<sup><xref ref-type="bibr" rid="bibr111-2040622320905215">111</xref></sup> reading performance and smooth pursuit eye movement compared with healthy controls.<sup><xref ref-type="bibr" rid="bibr105-2040622320905215">105</xref></sup> Deficits in the magnocellular pathway have also been implicated in some of the cognitive impairments seen,<sup><xref ref-type="bibr" rid="bibr112-2040622320905215">112</xref>,<xref ref-type="bibr" rid="bibr113-2040622320905215">113</xref></sup> including attention and memory.<sup><xref ref-type="bibr" rid="bibr107-2040622320905215">107</xref>,<xref ref-type="bibr" rid="bibr114-2040622320905215">114</xref></sup> Given the multiple visual symptomology in schizophrenia, various methods have been used to investigate the potential impact of magnocellular pathway deficits on vision. Functional magnetic resonance imaging (fMRI) studies have revealed right hemisphere magnocellular pathway hypoactivation in first-degree nonpsychotic relatives and patients with schizophrenia,<sup><xref ref-type="bibr" rid="bibr115-2040622320905215">115</xref></sup> but otherwise normal pathway functioning.<sup><xref ref-type="bibr" rid="bibr116-2040622320905215">116</xref></sup> Electroencephalography (EEG) studies measuring event-related potentials (ERPs) have shown diminished amplitudes and poor detection of low spatial frequency targets.<sup><xref ref-type="bibr" rid="bibr117-2040622320905215">117</xref></sup> Regarding contrast sensitivity loss, a review by Skottun and Skyoles concluded that contrast sensitivity deficits were not consistent with magnocellular deficiencies.<sup><xref ref-type="bibr" rid="bibr118-2040622320905215">118</xref></sup> However, they did acknowledge the difficulty of drawing a clear relationship between clinical symptoms of schizophrenia to deficits in the magnocellular pathway,<sup><xref ref-type="bibr" rid="bibr118-2040622320905215">118</xref></sup> such as linking poor reading performance in schizophrenia to dyslexia, which is weakly associated.<sup><xref ref-type="bibr" rid="bibr105-2040622320905215">105</xref></sup></p>
<p>More notably used in glaucoma, frequency doubling perimetry (FDT) is a small, transportable device that assesses visual field defects as well as changes in contrast sensitivity.<sup><xref ref-type="bibr" rid="bibr114-2040622320905215">114</xref></sup> FDT works by creating an illusion at a high temporal frequency of a counter-phased flicker of a sinusoidal grating with a low spatial frequency.<sup><xref ref-type="bibr" rid="bibr114-2040622320905215">114</xref></sup> Since processing this type of visual stimuli is believed to involve areas of the brain that process visual information that activate the magnocellular pathway, FDT is seen as a way to assess retinal ganglion cell (RGC) function.<sup><xref ref-type="bibr" rid="bibr115-2040622320905215">115</xref>,<xref ref-type="bibr" rid="bibr119-2040622320905215">119</xref>,<xref ref-type="bibr" rid="bibr120-2040622320905215">120</xref></sup> FDT has been used in glaucoma patients to assess the relationship between ganglion cell-inner plexiform layer (GCIPL) thickness and mean sensitivities and showed strong statistically significant positive correlations between the two, most notably in the inferotemporal and inferior sectors.<sup><xref ref-type="bibr" rid="bibr121-2040622320905215">121</xref></sup> Several studies have explored neurological dysfunction of this pathway in patients with schizophrenia using FDT as well. Khosravani and Goodarzi reported diminished visual field sensitivity in patients with schizophrenia compared with normal controls.<sup><xref ref-type="bibr" rid="bibr106-2040622320905215">106</xref></sup> Gracitelli and colleagues reported statistically significantly lower global mean deviation in both eyes of patients with schizophrenia compared with their parents and normal controls.<sup><xref ref-type="bibr" rid="bibr107-2040622320905215">107</xref></sup> Similarly, Lima and colleagues showed lower global mean sensitivity in patients compared with healthy controls.<sup><xref ref-type="bibr" rid="bibr108-2040622320905215">108</xref></sup> Indeed, these abnormalities may reflect deeper damage to neural pathways within the brain, specifically the cortex and brainstem, as similarly proposed in AD,<sup><xref ref-type="bibr" rid="bibr122-2040622320905215">122</xref></sup> in order to offer a potential biomarker for diagnosis and monitoring of cognitive impairment in schizophrenia, thus an area of great interest for future research.</p>
</sec>
<sec id="section8-2040622320905215">
<title>Severity and duration of schizophrenia</title>
<p>The correlations reported between duration of disease with retinal thickness and macular volume are mixed. Significant inverse correlations have been reported between duration of disease and thickness of the RNFL, temporal parafoveal ISL and temporal parafoveal ONL, as well as macular thinning and volume.<sup><xref ref-type="bibr" rid="bibr61-2040622320905215">61</xref>,<xref ref-type="bibr" rid="bibr62-2040622320905215">62</xref></sup> These correlations with macula thickness and volume suggest progressive neurodegeneration seen in parallel with MRI changes of grey matter volume loss.<sup><xref ref-type="bibr" rid="bibr123-2040622320905215">123</xref></sup> However, studies containing similar numbers of patients and controls have reported no significant correlation between RNFL thickness or macular thickness with duration of illness.<sup><xref ref-type="bibr" rid="bibr74-2040622320905215">74</xref>,<xref ref-type="bibr" rid="bibr79-2040622320905215">79</xref></sup> The Ascaso study (<italic>n</italic> = 60) found no correlation between duration and retinal abnormalities; however, the finding of macular thinning in patients with nonrecent illness episodes suggests that changes in retinal structures may be conditional as opposed to progressive.<sup><xref ref-type="bibr" rid="bibr75-2040622320905215">75</xref></sup> Similarly, Chu and colleagues reported no significant retinal changes between early stage schizophrenia patients and schizoaffective disorder to age and gender-matched controls.<sup><xref ref-type="bibr" rid="bibr82-2040622320905215">82</xref></sup> The lack of disease-related retinal changes seen in these studies may be explained by the theory that lower levels of neuroinflammation in the retina can be caused by antipsychotic drug use, particularly in patients with recent illness episodes.<sup><xref ref-type="bibr" rid="bibr124-2040622320905215">124</xref>,<xref ref-type="bibr" rid="bibr125-2040622320905215">125</xref></sup> This has been supported by a meta-analysis that included 23 studies (<italic>n</italic> = 762), which suggested antipsychotics express a systemic anti-inflammatory effect.<sup><xref ref-type="bibr" rid="bibr126-2040622320905215">126</xref></sup> Only one study we reviewed actively assessed the role of antipsychotics on OCT abnormalities, and found no significant correlation with treatment.<sup><xref ref-type="bibr" rid="bibr61-2040622320905215">61</xref></sup></p>
<p>The relationship between the severity of symptoms and retinal abnormalities is also unclear. Thinning of the RNFL, GCL and IPL have been found to significantly correlate with disease severity, measured by the Positive and Negative Symptom Scale (PANSS).<sup><xref ref-type="bibr" rid="bibr72-2040622320905215">72</xref>,<xref ref-type="bibr" rid="bibr127-2040622320905215">127</xref></sup> Moreover, GCL and IPL volumes have been found to be lower in treatment refractory patients with schizophrenia compared to treatment responsive patients,<sup><xref ref-type="bibr" rid="bibr72-2040622320905215">72</xref></sup> suggesting an inverse relationship with advanced disease. A more recent study observed that ONL and foveal photoreceptor thinning significantly correlated with the severity of negative symptoms, in addition to a significant inverse correlation with nasal parafoveal ONL thickness.<sup><xref ref-type="bibr" rid="bibr61-2040622320905215">61</xref></sup> Smaller macular volume has also been related to higher severity of symptoms using the Schedules for the Assessment of Positive and Negative Symptoms (SAPS and SANS) scales.<sup><xref ref-type="bibr" rid="bibr82-2040622320905215">82</xref>,<xref ref-type="bibr" rid="bibr128-2040622320905215">128</xref></sup> However, similar studies with respect to number of patients and age or gender-matched controls, have reported no significant correlation between RNFL thickness or macular thickness with severity measured by the Clinical Global Impression Scale-Severity (CGI-S)<sup><xref ref-type="bibr" rid="bibr129-2040622320905215">129</xref></sup> and PANSS scores, respectively.<sup><xref ref-type="bibr" rid="bibr74-2040622320905215">74</xref>,<xref ref-type="bibr" rid="bibr79-2040622320905215">79</xref></sup></p>
</sec>
<sec id="section9-2040622320905215">
<title>Future possibilities in schizophrenia</title>
<p>Firstly, animal models representing negative symptoms are lacking. It has proven difficult to model schizophrenia in animals given that the disease impairs higher brain function resulting in human-specific symptoms such as delusions, hallucinations and disorganised speech.<sup><xref ref-type="bibr" rid="bibr130-2040622320905215">130</xref></sup> Animal models in schizophrenia are few, and tend to focus on dopamine dysfunction driving pathophysiological changes.<sup><xref ref-type="bibr" rid="bibr131-2040622320905215">131</xref>,<xref ref-type="bibr" rid="bibr132-2040622320905215">132</xref></sup> These have shown that retinal dopaminergic deficiency may lead to loss of a subset of retinal amacrine cells.<sup><xref ref-type="bibr" rid="bibr133-2040622320905215">133</xref></sup> Treatments for negative and cognitive symptoms of schizophrenia are lacking, hence more work is needed to develop comprehensive models that will adequately reproduce the deficits created by these symptoms. Secondly, given the contentious nature of findings related to retinal thinning, macular thinning and macular volume deficits, larger studies that evaluate more detailed and comprehensive outcome measures are necessary. This would include higher resolution OCT scans adequate enough to visualise subtle abnormalities present in early schizophrenia. Chu and colleagues acknowledged lower resolution time-domain OCT (axial resolution 10 μm) as the main limitation of their study, whereas studies that offered better axial resolution of 5 μm yielded more significant macular thickness measurements.<sup><xref ref-type="bibr" rid="bibr61-2040622320905215">61</xref>,<xref ref-type="bibr" rid="bibr62-2040622320905215">62</xref>,<xref ref-type="bibr" rid="bibr82-2040622320905215">82</xref></sup> Thirdly, most schizophrenia patients in these studies were receiving antipsychotic medications at the time of data collection, therefore it was not possible to exclude the potential anti-inflammatory and neuroprotective effects of these medications that may have masked minor differences in RNFL between the different groups.<sup><xref ref-type="bibr" rid="bibr134-2040622320905215">134</xref></sup> Finally, tobacco smoking is very common in schizophrenia and has been suggested to have a procognitive effect on positive symptoms,<sup><xref ref-type="bibr" rid="bibr135-2040622320905215">135</xref></sup> although a recent study by Yokoyama and colleagues discovered an association between length of smoking and severe symptoms with reduced prefrontal volume on MRI.<sup><xref ref-type="bibr" rid="bibr136-2040622320905215">136</xref></sup> Additionally, chronic tobacco smokers have been shown to have a thinner ganglion cell complex and choroid compared with age and sex-matched nonsmoking controls, suggesting that smoking may confound or modify the effect of the relationship between retinal thinning and schizophrenia (<xref ref-type="table" rid="table2-2040622320905215">Table 2</xref>).<sup><xref ref-type="bibr" rid="bibr136-2040622320905215">136</xref>,<xref ref-type="bibr" rid="bibr137-2040622320905215">137</xref></sup></p>
</sec>
</sec>
<sec id="section10-2040622320905215">
<title>Bipolar disorder</title>
<p>Bipolar disorder (BD), formerly known as manic depression, is an episodic, chronic psychiatric illness that can cause severe disability and declines in quality of life.<sup><xref ref-type="bibr" rid="bibr138-2040622320905215">138</xref></sup> Patients with BD experience severe mood swings from intense highs (mania) to extreme lows (depression) that last for several weeks or months. An estimated 1% of the global population is affected by BD,<sup><xref ref-type="bibr" rid="bibr138-2040622320905215">138</xref></sup> and it has been estimated that between 30% and 50% of patients with BD have been misdiagnosed with unipolar major depression because of initial presentation with a depressive episode, and may go on for years without a correct diagnosis.<sup><xref ref-type="bibr" rid="bibr139-2040622320905215">139</xref><xref ref-type="bibr" rid="bibr140-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr141-2040622320905215">141</xref></sup> Delayed diagnosis, especially in children and adolescents,<sup><xref ref-type="bibr" rid="bibr142-2040622320905215">142</xref>,<xref ref-type="bibr" rid="bibr143-2040622320905215">143</xref></sup> has been linked with poorer outcomes, including longer episodes and higher rates of recurrence.<sup><xref ref-type="bibr" rid="bibr144-2040622320905215">144</xref><xref ref-type="bibr" rid="bibr145-2040622320905215"></xref><xref ref-type="bibr" rid="bibr146-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr147-2040622320905215">147</xref></sup> Structural brain abnormalities seen on MRI have been detected in patients as early as the first episode, with some changes progressing, including reduced grey matter in the hippocampus, temporal lobe and fusiform gyrus.<sup><xref ref-type="bibr" rid="bibr148-2040622320905215">148</xref>,<xref ref-type="bibr" rid="bibr149-2040622320905215">149</xref></sup></p>
<sec id="section11-2040622320905215">
<title>RNFL changes in bipolar disorder</title>
<p>More recently, OCT has been used to correlate these changes in the retina. Multiple studies have demonstrated statistically significant global thinning of the pRNFL in patients (<xref ref-type="table" rid="table1-2040622320905215">Table 1</xref>).<sup><xref ref-type="bibr" rid="bibr83-2040622320905215">83</xref>,<xref ref-type="bibr" rid="bibr84-2040622320905215">84</xref>,<xref ref-type="bibr" rid="bibr86-2040622320905215">86</xref>,<xref ref-type="bibr" rid="bibr150-2040622320905215">150</xref></sup> Compared with healthy controls, statistically significant global RNFL thinning was observed in euthymic (current ‘normal’ mood) BD patients.<sup><xref ref-type="bibr" rid="bibr84-2040622320905215">84</xref></sup> However, similar studies that age-matched controls have observed all but temporal thinning.<sup><xref ref-type="bibr" rid="bibr83-2040622320905215">83</xref></sup> Conversely, using age and sex-matched controls led to the observation of all but nasal thinning.<sup><xref ref-type="bibr" rid="bibr85-2040622320905215">85</xref>,<xref ref-type="bibr" rid="bibr150-2040622320905215">150</xref></sup> Studies that measured antipsychotic use did not find a correlation between prescribed medications and RNFL thinning, hence patients presented with significant RNFL thinning regardless of antipsychotic use.<sup><xref ref-type="bibr" rid="bibr84-2040622320905215">84</xref>,<xref ref-type="bibr" rid="bibr150-2040622320905215">150</xref></sup> In addition, duration of illness has been shown to negatively correlate with RNFL thickness and GCC volume in euthymic and psychotic patients, suggesting a progressive neurodegenerative process.<sup><xref ref-type="bibr" rid="bibr83-2040622320905215">83</xref>,<xref ref-type="bibr" rid="bibr84-2040622320905215">84</xref></sup></p>
<p>Multiple studies have observed lower IPL and GCL volume in BD patients,<sup><xref ref-type="bibr" rid="bibr84-2040622320905215">84</xref>,<xref ref-type="bibr" rid="bibr85-2040622320905215">85</xref>,<xref ref-type="bibr" rid="bibr150-2040622320905215">150</xref></sup> and a significant negative correlation between severity and duration of illness.<sup><xref ref-type="bibr" rid="bibr84-2040622320905215">84</xref></sup> One study observed a significant compensatory thickening of the INL in the BD group,<sup><xref ref-type="bibr" rid="bibr150-2040622320905215">150</xref></sup> contrary to previous BD studies, but similar to reported findings in Parkinson disease.<sup><xref ref-type="bibr" rid="bibr151-2040622320905215">151</xref></sup> Therefore, the absence of more observations of total retinal thickness change in BD may be a result of masking of thinning by simultaneous thickening of other layers.<sup><xref ref-type="bibr" rid="bibr150-2040622320905215">150</xref></sup> Newer, swept-source OCT able to image both the retina and choroid has been used to examine patients with BD, demonstrating significant thinning in the central macula, as well as in the inner temporal, nasal and inferior zones (<xref ref-type="table" rid="table2-2040622320905215">Table 2</xref>).<sup><xref ref-type="bibr" rid="bibr86-2040622320905215">86</xref></sup> However, no changes in choroidal thickness were observed.</p>
</sec>
<sec id="section12-2040622320905215">
<title>ERG changes in bipolar disorder</title>
<p>Patients at high genetic risk for BD (<italic>n</italic> = 20) and schizophrenia (<italic>n</italic> = 9) (one parent with BD or schizophrenia) have demonstrated diminished rod b-wave amplitude and delayed latency compared with age and sex-matched healthy controls, but no statistical difference in cones.<sup><xref ref-type="bibr" rid="bibr152-2040622320905215">152</xref></sup> A more recent and larger follow up study comparing high-risk children with age- and sex-matched healthy controls also observed diminished rod b-wave amplitude and delayed latency but also found delayed cone b-wave latency.<sup><xref ref-type="bibr" rid="bibr153-2040622320905215">153</xref></sup> These results suggest that retinal rod response abnormalities may serve as a biomarker for the risk of developing BD.</p>
</sec>
<sec id="section13-2040622320905215">
<title>Future possibilities in bipolar disorder</title>
<p>Few studies have assessed the structural and functional changes in the retina associated with BD directly. Growing evidence from OCT studies suggests neurodegeneration in BD can be characterized by RNFL, GCL and IPL thinning with increasing duration of disease.<sup><xref ref-type="bibr" rid="bibr83-2040622320905215">83</xref><xref ref-type="bibr" rid="bibr84-2040622320905215"></xref><xref ref-type="bibr" rid="bibr85-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr86-2040622320905215">86</xref></sup> The pathophysiological changes that underpin these observations remain unclear, hence more research is needed to support these findings. A potential explanation could be that low retinal dopamine, as suggested by reduced b-wave amplitude, may play a part in hypo-arousal states (anhedonia, melancholia) as suggested in seasonal affective disorder (SAD).<sup><xref ref-type="bibr" rid="bibr154-2040622320905215">154</xref>,<xref ref-type="bibr" rid="bibr155-2040622320905215">155</xref></sup> Still, small study size, chronic medication use and early age of onset are just a few of the barriers to establishing OCT, ERG and other similar measures as valid biomarkers to show degeneration and follow progression of BD and other psychiatric disorders.</p>
</sec>
</sec>
<sec id="section14-2040622320905215">
<title>Major depression</title>
<p>Major depression (MD) is a neuropsychiatric disorder that can affect individuals across a life span. MD is marked by anhedonia, low mood and cognitive disturbances.<sup><xref ref-type="bibr" rid="bibr156-2040622320905215">156</xref></sup> According to WHO estimates, depression is the leading cause of disability worldwide.<sup><xref ref-type="bibr" rid="bibr157-2040622320905215">157</xref></sup> It is estimated that over 322 million people suffer from depression, 4.4% of the world’s population. A number of risk factors have been identified, including female gender, high stress, family history, childhood experiences, personality traits and genetics.<sup><xref ref-type="bibr" rid="bibr158-2040622320905215">158</xref><xref ref-type="bibr" rid="bibr159-2040622320905215"></xref><xref ref-type="bibr" rid="bibr160-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr161-2040622320905215">161</xref></sup> It has been observed that healthy patients who self-report visual impairment without visual acuity loss have almost double the odds of depression compared with visual acuity loss alone, after controlling for other risk factors.<sup><xref ref-type="bibr" rid="bibr162-2040622320905215">162</xref></sup> This finding could either be due to changes in the brain–vision axis, or other psychological influences.</p>
<p>The role of neuroinflammation has recently been implicated in the aetiology of MD, as evidenced by activation of the immune system seen in depressed patients and the strong relationship observed between depression and autoimmune diseases.<sup><xref ref-type="bibr" rid="bibr163-2040622320905215">163</xref><xref ref-type="bibr" rid="bibr164-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr165-2040622320905215">165</xref></sup> By one estimate, up to 50% of autoimmune patients exhibit impaired quality of life or depressive symptoms.<sup><xref ref-type="bibr" rid="bibr166-2040622320905215">166</xref></sup> Moreover, increasing evidence has pointed to the importance of neuroinflammation in AD pathogenesis,<sup><xref ref-type="bibr" rid="bibr167-2040622320905215">167</xref><xref ref-type="bibr" rid="bibr168-2040622320905215"></xref><xref ref-type="bibr" rid="bibr169-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr170-2040622320905215">170</xref></sup> and history of MD as a risk factor for AD.<sup><xref ref-type="bibr" rid="bibr171-2040622320905215">171</xref><xref ref-type="bibr" rid="bibr172-2040622320905215"></xref><xref ref-type="bibr" rid="bibr173-2040622320905215"></xref><xref ref-type="bibr" rid="bibr174-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr175-2040622320905215">175</xref></sup> Likewise, MRI and postmortem studies have shown decreased grey matter volume and glial density in the prefrontal and cingulate cortices and decreased hippocampal volume in patients with depression, regions of the brain involved in the emotional and cognitive characteristics of depression.<sup><xref ref-type="bibr" rid="bibr176-2040622320905215">176</xref><xref ref-type="bibr" rid="bibr177-2040622320905215"></xref><xref ref-type="bibr" rid="bibr178-2040622320905215"></xref><xref ref-type="bibr" rid="bibr179-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr180-2040622320905215">180</xref></sup> In MRI studies, decreased volumes in the prefrontal cortex, hippocampus and basal ganglia have been found bilaterally.<sup><xref ref-type="bibr" rid="bibr180-2040622320905215">180</xref></sup> It is also important to note that the shape of the hippocampus has been found to be abnormal in MD patients without volume deficits through high-dimensional mapping.<sup><xref ref-type="bibr" rid="bibr181-2040622320905215">181</xref></sup> Based on these findings, several studies have been conducted to investigate the relationship between these changes and functional and structural retinal changes related to MD.</p>
<sec id="section15-2040622320905215">
<title>ERG findings in major depression</title>
<p>ERG changes have been described in several studies of MD patients. The largest of these studies (<italic>n</italic> = 200) comparing the cone and rod ERGs between MD patients and healthy controls observed prolonged b-waves at the cone level and reduced rods/cone a-waves in medicated and unmedicated MD patients compared with controls, suggesting that these irregularities are not modifiable by medication.<sup><xref ref-type="bibr" rid="bibr182-2040622320905215">182</xref></sup> In contrast, another smaller (<italic>n</italic> = 40) study assessing the response to duloxetine in MD patients and healthy controls found that treatment-responsive MD patients had significantly higher baseline rod b-wave amplitudes compared with nonresponders and healthy controls; however, no statistical difference between all groups was found at 12 weeks.<sup><xref ref-type="bibr" rid="bibr183-2040622320905215">183</xref></sup> Their findings suggest that rod b-wave amplitude alterations could be state-dependent or potentially predict response to antidepressants in subtypes of depression.</p>
<p>Significant reductions in pattern electroretinogram (PERG) amplitude have been observed in MD patients compared with controls; unmedicated and medicated MD patients displayed significantly lower retinal contrast gain compared with controls. In addition, studies have found a strong correlation between contrast gain and depression severity.<sup><xref ref-type="bibr" rid="bibr184-2040622320905215">184</xref></sup> In those patients who achieved remission, MD patients with low baseline contrast gains normalised on par with controls, whereas patients not achieving remission continued to show reduced RGC function, providing evidence that retinal contrast gains may be state-dependent and therefore useful as a prognostic biomarker.<sup><xref ref-type="bibr" rid="bibr185-2040622320905215">185</xref></sup> Moreover, as mentioned previously and similar to BD, reduced b-wave amplitude may be indicative of low retinal dopamine, contributing to hypo-arousal as seen in SAD.<sup><xref ref-type="bibr" rid="bibr154-2040622320905215">154</xref>,<xref ref-type="bibr" rid="bibr155-2040622320905215">155</xref></sup></p>
</sec>
<sec id="section16-2040622320905215">
<title>Wide retinal venules</title>
<p>There is strong evidence from longitudinal studies that patients with MD are at increased risk of developing cardiovascular disease.<sup><xref ref-type="bibr" rid="bibr186-2040622320905215">186</xref><xref ref-type="bibr" rid="bibr187-2040622320905215"></xref><xref ref-type="bibr" rid="bibr188-2040622320905215"></xref><xref ref-type="bibr" rid="bibr189-2040622320905215"></xref><xref ref-type="bibr" rid="bibr190-2040622320905215"></xref><xref ref-type="bibr" rid="bibr191-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr192-2040622320905215">192</xref></sup> In light of this risk, a large (<italic>n</italic> = 865) cross-sectional study based on the cohorts from the Brisbane Longitudinal Twin Study and the Twin Eye Study in Tasmania examined whether an association existed between depression and anxiety with retinal vessel calibre. In the adolescents and young adults who participated, depression and anxiety symptoms were associated with wider retinal venules, even after adjusting for other cardiovascular risk factors.<sup><xref ref-type="bibr" rid="bibr193-2040622320905215">193</xref></sup></p>
</sec>
<sec id="section17-2040622320905215">
<title>OCT in major depression</title>
<p><italic>In vivo</italic> visualization of the retina <italic>via</italic> OCT in MD patients has been explored by several studies, with mixed findings (<xref ref-type="table" rid="table1-2040622320905215">Table 1</xref>). Significantly reduced GCL, IPL and global and temporal superior RNFL thickness have been observed in recurrent MD patients compared with first episode patients, and in all MD patients compared with healthy controls.<sup><xref ref-type="bibr" rid="bibr194-2040622320905215">194</xref></sup> However, most of the evidence comparing MD patients with healthy controls to date found no statistically significant difference in OCT measures although differences within MD groups were more profound (<xref ref-type="table" rid="table1-2040622320905215">Table 1</xref>).<sup><xref ref-type="bibr" rid="bibr87-2040622320905215">87</xref>,<xref ref-type="bibr" rid="bibr88-2040622320905215">88</xref>,<xref ref-type="bibr" rid="bibr195-2040622320905215">195</xref></sup> Duration and severity of disease was observed to correlate negatively with GCL and IPL volumes and positively with global RNFL thickness; however, the evidence is weak for all measures possibly owing to the majority of MD patients taking psychotropic medication.<sup><xref ref-type="bibr" rid="bibr87-2040622320905215">87</xref>,<xref ref-type="bibr" rid="bibr194-2040622320905215">194</xref></sup> Finally, the total retinal volume of the left eye has been shown to be greater than the right eye in MD patients, indicating a possible hemisphere-specific lateralisation of cognitive processing.<sup><xref ref-type="bibr" rid="bibr195-2040622320905215">195</xref></sup> This idea has been compounded by positron emission tomography (PET) studies showing increased orbitofrontal and prefrontal activity in healthy volunteers during temporary states of sadness,<sup><xref ref-type="bibr" rid="bibr196-2040622320905215">196</xref>,<xref ref-type="bibr" rid="bibr197-2040622320905215">197</xref></sup> with MD patients more often having altered left prefrontal functioning.<sup><xref ref-type="bibr" rid="bibr198-2040622320905215">198</xref><xref ref-type="bibr" rid="bibr199-2040622320905215"></xref><xref ref-type="bibr" rid="bibr200-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr201-2040622320905215">201</xref></sup></p>
</sec>
<sec id="section18-2040622320905215">
<title>Future possibilities in major depression</title>
<p>Compared with other diseases included in this review, there is a dearth of evidence defining the structural and functional changes in the retina in MD. More studies are required to confirm the presence or absence of retinal changes between MD patients and healthy controls, severity of symptoms, duration of illness, timing of depressive episodes, effect of antidepressant use and how they may relate to future neurodegeneration. The lack of differences between MD patients and controls seen in studies may be a real absence of effect, or alternatively due to small study numbers, insufficient resolution of OCT or other methodological issues. For example, retinal thickness has been found to fluctuate according to diurnal variations in healthy patients, yet no study reviewed here reported timing of examinations, which could explain the lack of difference seen between MD patients and the control group, if not standardized.<sup><xref ref-type="bibr" rid="bibr202-2040622320905215">202</xref><xref ref-type="bibr" rid="bibr203-2040622320905215"></xref><xref ref-type="bibr" rid="bibr204-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr205-2040622320905215">205</xref></sup> As suggested by the monoamine deficiency hypothesis, the pathophysiology of MD may result from deficiencies in norepinephrine, serotonin and dopamine.<sup><xref ref-type="bibr" rid="bibr206-2040622320905215">206</xref><xref ref-type="bibr" rid="bibr207-2040622320905215"></xref>–<xref ref-type="bibr" rid="bibr208-2040622320905215">208</xref></sup> Therefore, if retinal dopamine, released by amacrine cells in the INL, is diminished, subsequent input to retinal ganglion cells is reduced and could lead to atrophy in these layers as noted on OCT.<sup><xref ref-type="bibr" rid="bibr209-2040622320905215">209</xref></sup> Therefore, OCT may be an important tool to track neurodegeneration in patients with MD, yet few studies have investigated its role longitudinally, possibly due to the statistically insignificant findings thus far.<sup><xref ref-type="bibr" rid="bibr194-2040622320905215">194</xref></sup> Advancements in OCT imaging technology assure high-resolution images that will, in the future, allow any structural changes to be detected with greater sensitivity, in particular the GCL.<sup><xref ref-type="bibr" rid="bibr210-2040622320905215">210</xref></sup></p>
</sec>
</sec>
<sec id="section19-2040622320905215" sec-type="conclusions">
<title>Conclusion</title>
<p>The studies reviewed propose that various changes in structure and function of the retina reflect changes in the brain and could thus serve as important biomarkers in psychiatric disorders. In schizophrenia, the hyper- and hypoactivity of NMDA glutamatergic receptor found at the fovea could potentially be associated with functional changes, but more studies are needed, observing retinal changes over time. It is well accepted that dopamine abnormalities, which also may be linked to positive and negative symptoms, impair visual function. Additionally, OCT has revealed retinal thinning and reduced macular volume and thickness in schizophrenia; however, it is unclear if these findings correlate with duration and severity of symptoms. Moreover, it is unknown how RNFL thinning relates to atrophy of specific regions of the brain in schizophrenia and MD.<sup><xref ref-type="bibr" rid="bibr78-2040622320905215">78</xref></sup> In particular, if occipital atrophy does occur, knowing when it occurs in relation to RNFL thinning could help explain why some studies have found no difference in RNFL thickness between patients with schizophrenia and controls despite visual symptomology.<sup><xref ref-type="bibr" rid="bibr82-2040622320905215">82</xref></sup> Lessons may be learned from a similar finding of absent retinal thinning with visual disturbances in anti-NMDA receptor encephalitis, pointing, instead, to potential dysfunction in the anterior and posterior visual pathways and thus demonstrating deeper cortical and subcortical processing impairments in the brain.<sup><xref ref-type="bibr" rid="bibr211-2040622320905215">211</xref></sup> It also must be noted that the majority of studies reviewed reported exclusion of patients with concomitant ocular diseases; however, it is less clear whether diseases that could inevitably affect ocular structure and function, such as diabetes, were excluded or controlled for.</p>
<p>In BD, OCT has demonstrated pRNFL thinning, and lower IPL and GCL with increasing duration of disease, thus proposing a potential method to aid in early diagnosis of this disease. Moreover, ERG has allowed for observation of diminished rod b-wave amplitude and delayed cone b-wave latency in bipolar patients with high genetic risks. On the other hand, in major depression, prolonged b-waves at the cone level were found, suggesting that ERG could serve as a valuable tool to evaluate antidepressant response and differentiate between bipolar disorder and depression during diagnosis. Despite many structural and functional changes in the retina of patients with MD, there is a gap in understanding how these biomarkers can aid practice at the clinical level. In all these conditions, if a long-term biomarker (over decades) might be found in the retina, it is unlikely to replace functional and behavioural outcomes, as these are what are assumed to cause the disability in these psychiatric illnesses as opposed to poor vision. However, it may serve as a surrogate endpoint.</p>
<p>Major advances in retinal imaging in recent years, specifically with OCT, have enabled the discovery of these potential biomarkers. The results from these studies demonstrate how retinal biomarkers could help robust clinical diagnostic methods and the monitoring of disease progression. Since much of the existing research is limited by cross-sectional designs, further studies utilising more robust methods, such as cohorts, with large and sufficiently powered sample sizes are key to developing a more comprehensive understanding the relationship between OCT measures and psychiatric disorders and establishing retinal biomarkers that are reliable enough to diagnose psychiatric conditions early on, potentially predicting disease onset and severity before symptoms manifest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding:</bold> The author(s) received no financial support for the research, authorship, and publication of this article.</p>
</fn>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest statement:</bold> The authors declare that there is no conflict of interest.</p>
</fn>
<fn fn-type="other">
<p><bold>ORCID iD:</bold> Maria Francesca Cordeiro <inline-graphic xlink:href="10.1177_2040622320905215-img1.jpg"></inline-graphic>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0001-8663-6525">https://orcid.org/0000-0001-8663-6525</ext-link></p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2040622320905215">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whiteford</surname><given-names>HA</given-names></name><name><surname>Degenhardt</surname><given-names>L</given-names></name><name><surname>Rehm</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010</article-title>. <source/>Lancet
<year>2013</year>; <volume>382</volume>: <fpage>1575</fpage>–<lpage>1586</lpage>.<pub-id pub-id-type="pmid">23993280</pub-id></mixed-citation>
</ref>
<ref id="bibr2-2040622320905215">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vigo</surname><given-names>D</given-names></name><name><surname>Thornicroft</surname><given-names>G</given-names></name><name><surname>Atun</surname><given-names>R.</given-names></name></person-group>
<article-title>Estimating the true global burden of mental illness</article-title>. <source/>Lancet Psychiatry
<year>2016</year>; <volume>3</volume>: <fpage>171</fpage>–<lpage>178</lpage>.<pub-id pub-id-type="pmid">26851330</pub-id></mixed-citation>
</ref>
<ref id="bibr3-2040622320905215">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steel</surname><given-names>Z</given-names></name><name><surname>Marnane</surname><given-names>C</given-names></name><name><surname>Iranpour</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>The global prevalence of common mental disorders: a systematic review and meta-analysis 1980-2013</article-title>. <source/>Int J Epidemiol
<year>2014</year>; <volume>43</volume>: <fpage>476</fpage>–<lpage>493</lpage>.<pub-id pub-id-type="pmid">24648481</pub-id></mixed-citation>
</ref>
<ref id="bibr4-2040622320905215">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ginn</surname><given-names>S</given-names></name><name><surname>Horder</surname><given-names>J.</given-names></name></person-group>
<article-title>“One in four” with a mental health problem: the anatomy of a statistic</article-title>. <source/>BMJ
<year>2012</year>; <volume>344</volume>: <fpage>e1302</fpage>.<pub-id pub-id-type="pmid">22362250</pub-id></mixed-citation>
</ref>
<ref id="bibr5-2040622320905215">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lancon</surname><given-names>C</given-names></name><name><surname>Martinelli</surname><given-names>M</given-names></name><name><surname>Michel</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>
<article-title>Psychiatric comorbidities and quality of life in adult individuals with high potential: relationships with self-esteem</article-title>. <source/>Presse Med
<year>2015</year>; <volume>44</volume>: <fpage>e177</fpage>–<lpage>e184</lpage>.<pub-id pub-id-type="pmid">25813095</pub-id></mixed-citation>
</ref>
<ref id="bibr6-2040622320905215">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>CM</given-names></name><name><surname>Lee</surname><given-names>IC</given-names></name><name><surname>Su</surname><given-names>YY</given-names></name></person-group>, <etal>et al</etal>
<article-title>The longitudinal relationship between mental health disorders and chronic disease for older adults: a population-based study</article-title>. <source/>Int J Geriatr Psychiatry
<year>2017</year>; <volume>32</volume>: <fpage>1017</fpage>–<lpage>1026</lpage>.<pub-id pub-id-type="pmid">27546556</pub-id></mixed-citation>
</ref>
<ref id="bibr7-2040622320905215">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>First</surname><given-names>MB</given-names></name><name><surname>Bhat</surname><given-names>V</given-names></name><name><surname>Adler</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>How do clinicians actually use the Diagnostic and Statistical Manual of Mental Disorders in clinical practice and why we need to know more</article-title>. <source/>J Nerv Ment Dis
<year>2014</year>; <volume>202</volume>: <fpage>841</fpage>–<lpage>844</lpage>.<pub-id pub-id-type="pmid">25390931</pub-id></mixed-citation>
</ref>
<ref id="bibr8-2040622320905215">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cederlund</surname><given-names>M</given-names></name><name><surname>Hagberg</surname><given-names>B</given-names></name><name><surname>Gillberg</surname><given-names>C.</given-names></name></person-group>
<article-title>Asperger syndrome in adolescent and young adult males. Interview, self- and parent assessment of social, emotional, and cognitive problems</article-title>. <source/>Res Dev Disabil
<year>2010</year>; <volume>31</volume>: <fpage>287</fpage>–<lpage>298</lpage>.<pub-id pub-id-type="pmid">19880274</pub-id></mixed-citation>
</ref>
<ref id="bibr9-2040622320905215">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies</article-title>. <source/>J Psychiatr Res
<year>2013</year>; <volume>47</volume>: <fpage>1549</fpage>–<lpage>1556</lpage>.<pub-id pub-id-type="pmid">23953755</pub-id></mixed-citation>
</ref>
<ref id="bibr10-2040622320905215">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lowe</surname><given-names>B</given-names></name><name><surname>Unutzer</surname><given-names>J</given-names></name><name><surname>Callahan</surname><given-names>CM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Monitoring depression treatment outcomes with the patient health questionnaire-9</article-title>. <source/>Med Care
<year>2004</year>; <volume>42</volume>: <fpage>1194</fpage>–<lpage>1201</lpage>.<pub-id pub-id-type="pmid">15550799</pub-id></mixed-citation>
</ref>
<ref id="bibr11-2040622320905215">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wittkampf</surname><given-names>K</given-names></name><name><surname>van Ravesteijn</surname><given-names>H</given-names></name><name><surname>Baas</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>The accuracy of Patient Health Questionnaire-9 in detecting depression and measuring depression severity in high-risk groups in primary care</article-title>. <source/>Gen Hosp Psychiatry
<year>2009</year>; <volume>31</volume>: <fpage>451</fpage>–<lpage>459</lpage>.<pub-id pub-id-type="pmid">19703639</pub-id></mixed-citation>
</ref>
<ref id="bibr12-2040622320905215">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kjaergaard</surname><given-names>M</given-names></name><name><surname>Arfwedson Wang</surname><given-names>CE</given-names></name><name><surname>Waterloo</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>A study of the psychometric properties of the Beck Depression Inventory-II, the Montgomery and Asberg Depression Rating Scale, and the Hospital Anxiety and Depression Scale in a sample from a healthy population</article-title>. <source/>Scand J Psychol
<year>2014</year>; <volume>55</volume>: <fpage>83</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="pmid">24256317</pub-id></mixed-citation>
</ref>
<ref id="bibr13-2040622320905215">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>H</given-names></name><name><surname>Fervaha</surname><given-names>G</given-names></name><name><surname>Remington</surname><given-names>G.</given-names></name></person-group>
<article-title>Reliability of a patient-reported outcome measure in schizophrenia: Results from back-to-back self-ratings</article-title>. <source/>Psychiatry Res
<year>2016</year>; <volume>244</volume>: <fpage>415</fpage>–<lpage>419</lpage>.<pub-id pub-id-type="pmid">27543916</pub-id></mixed-citation>
</ref>
<ref id="bibr14-2040622320905215">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Demirci</surname><given-names>O</given-names></name><name><surname>Calhoun</surname><given-names>VD.</given-names></name></person-group>
<article-title>Functional magnetic resonance imaging – implications for detection of schizophrenia</article-title>. <source/>Eur Neurol Rev
<year>2009</year>; <volume>4</volume>: <fpage>103</fpage>–<lpage>106</lpage>.<pub-id pub-id-type="pmid">21743814</pub-id></mixed-citation>
</ref>
<ref id="bibr15-2040622320905215">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>M</given-names></name><name><surname>Galione</surname><given-names>JN</given-names></name><name><surname>Ruggero</surname><given-names>CJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Are screening scales for bipolar disorder good enough to be used in clinical practice?</article-title>
<source/>Compr Psychiatry
<year>2011</year>; <volume>52</volume>: <fpage>600</fpage>–<lpage>606</lpage>.<pub-id pub-id-type="pmid">21406301</pub-id></mixed-citation>
</ref>
<ref id="bibr16-2040622320905215">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Svendsen</surname><given-names>AM</given-names></name><name><surname>Kessing</surname><given-names>LV</given-names></name><name><surname>Munkholm</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>Is there an association between subjective and objective measures of cognitive function in patients with affective disorders?</article-title>
<source/>Nord J Psychiatry
<year>2012</year>; <volume>66</volume>: <fpage>248</fpage>–<lpage>253</lpage>.<pub-id pub-id-type="pmid">22070515</pub-id></mixed-citation>
</ref>
<ref id="bibr17-2040622320905215">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Silverstein</surname><given-names>SM</given-names></name><name><surname>Rosen</surname><given-names>R.</given-names></name></person-group>
<article-title>Schizophrenia and the eye</article-title>. <source/>Schizophr Res Cogn
<year>2015</year>; <volume>2</volume>: <fpage>46</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">26345525</pub-id></mixed-citation>
</ref>
<ref id="bibr18-2040622320905215">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Doustar</surname><given-names>J</given-names></name><name><surname>Torbati</surname><given-names>T</given-names></name><name><surname>Black</surname><given-names>KL</given-names></name></person-group>, <etal>et al</etal>
<article-title>Optical coherence tomography in Alzheimer’s disease and other neurodegenerative diseases</article-title>. <source/>Front Neurol
<year>2017</year>; <volume>8</volume>: <fpage>701</fpage>.<pub-id pub-id-type="pmid">29312125</pub-id></mixed-citation>
</ref>
<ref id="bibr19-2040622320905215">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bussel</surname><given-names>II</given-names></name><name><surname>Wollstein</surname><given-names>G</given-names></name><name><surname>Schuman</surname><given-names>JS</given-names></name></person-group>
<article-title>OCT for glaucoma diagnosis, screening and detection of glaucoma progression</article-title>. <source/>Br J Ophthalmol
<year>2014</year>; <volume>98</volume>(<issue>Suppl. 2</issue>): <fpage>15</fpage>–<lpage>19</lpage>.</mixed-citation>
</ref>
<ref id="bibr20-2040622320905215">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Joe</surname><given-names>P</given-names></name><name><surname>Ahmad</surname><given-names>M</given-names></name><name><surname>Riley</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>A pilot study assessing retinal pathology in psychosis using optical coherence tomography: choroidal and macular thickness</article-title>. <source/>Psychiatry Res
<year>2018</year>; <volume>263</volume>: <fpage>158</fpage>–<lpage>161</lpage>.<pub-id pub-id-type="pmid">29567341</pub-id></mixed-citation>
</ref>
<ref id="bibr21-2040622320905215">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Xiang</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>
<article-title>Retinal nerve fiber layer thickness changes in Schizophrenia: a meta-analysis of case-control studies</article-title>. <source/>Psychiatry Res
<year>2018</year>; <volume>270</volume>: <fpage>786</fpage>–<lpage>791</lpage>.<pub-id pub-id-type="pmid">30551326</pub-id></mixed-citation>
</ref>
<ref id="bibr22-2040622320905215">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oberwahrenbrock</surname><given-names>T</given-names></name><name><surname>Traber</surname><given-names>GL</given-names></name><name><surname>Lukas</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Multicenter reliability of semiautomatic retinal layer segmentation using OCT</article-title>. <source/>Neurol Neuroimmunol Neuroinflamm
<year>2018</year>; <volume>5</volume>: <fpage>e449</fpage>.<pub-id pub-id-type="pmid">29552598</pub-id></mixed-citation>
</ref>
<ref id="bibr23-2040622320905215">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhugra</surname><given-names>D.</given-names></name></person-group>
<article-title>The global prevalence of schizophrenia</article-title>. <source/>PLoS Med
<year>2005</year>; <volume>2</volume>: <fpage>e151</fpage>; quiz e175.<pub-id pub-id-type="pmid">15916460</pub-id></mixed-citation>
</ref>
<ref id="bibr24-2040622320905215">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lora</surname><given-names>A</given-names></name><name><surname>Kohn</surname><given-names>R</given-names></name><name><surname>Levav</surname><given-names>I</given-names></name></person-group>, <etal>et al</etal>
<article-title>Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middle-income countries</article-title>. <source/>Bull World Health Organ
<year>2012</year>; <volume>90</volume>: <fpage>47</fpage>–<lpage>54</lpage>, 54A–54B.<pub-id pub-id-type="pmid">22271964</pub-id></mixed-citation>
</ref>
<ref id="bibr25-2040622320905215">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheniaux</surname><given-names>E</given-names></name><name><surname>Landeira-Fernandez</surname><given-names>J</given-names></name><name><surname>Versiani</surname><given-names>M.</given-names></name></person-group>
<article-title>The diagnoses of schizophrenia, schizoaffective disorder, bipolar disorder and unipolar depression: interrater reliability and congruence between DSM-IV and ICD-10</article-title>. <source/>Psychopathology
<year>2009</year>; <volume>42</volume>: <fpage>293</fpage>–<lpage>298</lpage>.<pub-id pub-id-type="pmid">19609099</pub-id></mixed-citation>
</ref>
<ref id="bibr26-2040622320905215">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chan</surname><given-names>MK</given-names></name><name><surname>Cooper</surname><given-names>JD</given-names></name><name><surname>Bahn</surname><given-names>S.</given-names></name></person-group>
<article-title>Commercialisation of biomarker tests for mental illnesses: advances and obstacles</article-title>. <source/>Trends Biotechnol
<year>2015</year>; <volume>33</volume>: <fpage>712</fpage>–<lpage>723</lpage>.<pub-id pub-id-type="pmid">26549771</pub-id></mixed-citation>
</ref>
<ref id="bibr27-2040622320905215">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yolken</surname><given-names>RH</given-names></name><name><surname>Dickerson</surname><given-names>FB</given-names></name><name><surname>Fuller Torrey</surname><given-names>E.</given-names></name></person-group>
<article-title>Toxoplasma and schizophrenia</article-title>. <source/>Parasite Immunol
<year>2009</year>; <volume>31</volume>: <fpage>706</fpage>–<lpage>715</lpage>.<pub-id pub-id-type="pmid">19825110</pub-id></mixed-citation>
</ref>
<ref id="bibr28-2040622320905215">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arango</surname><given-names>C</given-names></name><name><surname>Fraguas</surname><given-names>D</given-names></name><name><surname>Parellada</surname><given-names>M.</given-names></name></person-group>
<article-title>Differential neurodevelopmental trajectories in patients with early-onset bipolar and schizophrenia disorders</article-title>. <source/>Schizophr Bull
<year>2014</year>; <volume>40</volume>(<issue>Suppl. 2</issue>): <fpage>S138</fpage>–<lpage>146</lpage>.<pub-id pub-id-type="pmid">24371326</pub-id></mixed-citation>
</ref>
<ref id="bibr29-2040622320905215">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Quinones</surname><given-names>MP</given-names></name><name><surname>Kaddurah-Daouk</surname><given-names>R.</given-names></name></person-group>
<article-title>Metabolomics tools for identifying biomarkers for neuropsychiatric diseases</article-title>. <source/>Neurobiol Dis
<year>2009</year>; <volume>35</volume>: <fpage>165</fpage>–<lpage>176</lpage>.<pub-id pub-id-type="pmid">19303440</pub-id></mixed-citation>
</ref>
<ref id="bibr30-2040622320905215">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haijma</surname><given-names>SV</given-names></name><name><surname>Van Haren</surname><given-names>N</given-names></name><name><surname>Cahn</surname><given-names>W</given-names></name></person-group>, <etal>et al</etal>
<article-title>Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects</article-title>. <source/>Schizophr Bull
<year>2013</year>; <volume>39</volume>: <fpage>1129</fpage>–<lpage>1138</lpage>.<pub-id pub-id-type="pmid">23042112</pub-id></mixed-citation>
</ref>
<ref id="bibr31-2040622320905215">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>GW</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Jeong</surname><given-names>GW.</given-names></name></person-group>
<article-title>Whole brain volume changes and its correlation with clinical symptom severity in patients with schizophrenia: a DARTEL-based VBM study</article-title>. <source/>PLoS One
<year>2017</year>; <volume>12</volume>: <fpage>e0177251</fpage>.<pub-id pub-id-type="pmid">28520743</pub-id></mixed-citation>
</ref>
<ref id="bibr32-2040622320905215">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Larsen</surname><given-names>TK</given-names></name><name><surname>Melle</surname><given-names>I</given-names></name><name><surname>Auestad</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal>
<article-title>Early detection of psychosis: positive effects on 5-year outcome</article-title>. <source/>Psychol Med
<year>2011</year>; <volume>41</volume>: <fpage>1461</fpage>–<lpage>1469</lpage>.<pub-id pub-id-type="pmid">20942996</pub-id></mixed-citation>
</ref>
<ref id="bibr33-2040622320905215">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fusar-Poli</surname><given-names>P</given-names></name><name><surname>McGorry</surname><given-names>PD</given-names></name><name><surname>Kane</surname><given-names>JM.</given-names></name></person-group>
<article-title>Improving outcomes of first-episode psychosis: an overview</article-title>. <source/>World Psychiatry
<year>2017</year>; <volume>16</volume>: <fpage>251</fpage>–<lpage>265</lpage>.<pub-id pub-id-type="pmid">28941089</pub-id></mixed-citation>
</ref>
<ref id="bibr34-2040622320905215">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weickert</surname><given-names>CS</given-names></name><name><surname>Weickert</surname><given-names>TW</given-names></name><name><surname>Pillai</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Biomarkers in schizophrenia: a brief conceptual consideration</article-title>. <source/>Dis Markers
<year>2013</year>; <volume>35</volume>: <fpage>3</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">24167344</pub-id></mixed-citation>
</ref>
<ref id="bibr35-2040622320905215">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keri</surname><given-names>S</given-names></name><name><surname>Antal</surname><given-names>A</given-names></name><name><surname>Szekeres</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>Spatiotemporal visual processing in schizophrenia</article-title>. <source/>J Neuropsychiatry Clin Neurosci
<year>2002</year>; <volume>14</volume>: <fpage>190</fpage>–<lpage>196</lpage>.<pub-id pub-id-type="pmid">11983794</pub-id></mixed-citation>
</ref>
<ref id="bibr36-2040622320905215">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Slaghuis</surname><given-names>WL.</given-names></name></person-group>
<article-title>Contrast sensitivity for stationary and drifting spatial frequency gratings in positive- and negative-symptom schizophrenia</article-title>. <source/>J Abnorm Psychol
<year>1998</year>; <volume>107</volume>: <fpage>49</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">9505038</pub-id></mixed-citation>
</ref>
<ref id="bibr37-2040622320905215">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klosterkotter</surname><given-names>J</given-names></name><name><surname>Hellmich</surname><given-names>M</given-names></name><name><surname>Steinmeyer</surname><given-names>EM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Diagnosing schizophrenia in the initial prodromal phase</article-title>. <source/>Arch Gen Psychiatry
<year>2001</year>; <volume>58</volume>: <fpage>158</fpage>–<lpage>164</lpage>.<pub-id pub-id-type="pmid">11177117</pub-id></mixed-citation>
</ref>
<ref id="bibr38-2040622320905215">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nieman</surname><given-names>D</given-names></name><name><surname>Becker</surname><given-names>H</given-names></name><name><surname>van de Fliert</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Antisaccade task performance in patients at ultra high risk for developing psychosis</article-title>. <source/>Schizophr Res
<year>2007</year>; <volume>95</volume>: <fpage>54</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">17656071</pub-id></mixed-citation>
</ref>
<ref id="bibr39-2040622320905215">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kelemen</surname><given-names>O</given-names></name><name><surname>Kiss</surname><given-names>I</given-names></name><name><surname>Benedek</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>Perceptual and cognitive effects of antipsychotics in first-episode schizophrenia: the potential impact of GABA concentration in the visual cortex</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry
<year>2013</year>; <volume>47</volume>: <fpage>13</fpage>–<lpage>19</lpage>.<pub-id pub-id-type="pmid">23954737</pub-id></mixed-citation>
</ref>
<ref id="bibr40-2040622320905215">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Phillipson</surname><given-names>OT</given-names></name><name><surname>Harris</surname><given-names>JP.</given-names></name></person-group>
<article-title>Perceptual changes in schizophrenia: a questionnaire survey</article-title>. <source/>Psychol Med
<year>1985</year>; <volume>15</volume>: <fpage>859</fpage>–<lpage>866</lpage>.<pub-id pub-id-type="pmid">4080889</pub-id></mixed-citation>
</ref>
<ref id="bibr41-2040622320905215">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kiss</surname><given-names>I</given-names></name><name><surname>Fabian</surname><given-names>A</given-names></name><name><surname>Benedek</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>When doors of perception open: visual contrast sensitivity in never-medicated, first-episode schizophrenia</article-title>. <source/>J Abnorm Psychol
<year>2010</year>; <volume>119</volume>: <fpage>586</fpage>–<lpage>593</lpage>.<pub-id pub-id-type="pmid">20677847</pub-id></mixed-citation>
</ref>
<ref id="bibr42-2040622320905215">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schubert</surname><given-names>EW</given-names></name><name><surname>Henriksson</surname><given-names>KM</given-names></name><name><surname>McNeil</surname><given-names>TF.</given-names></name></person-group>
<article-title>A prospective study of offspring of women with psychosis: visual dysfunction in early childhood predicts schizophrenia-spectrum disorders in adulthood</article-title>. <source/>Acta Psychiatr Scand
<year>2005</year>; <volume>112</volume>: <fpage>385</fpage>–<lpage>393</lpage>.<pub-id pub-id-type="pmid">16223427</pub-id></mixed-citation>
</ref>
<ref id="bibr43-2040622320905215">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hayes</surname><given-names>JF</given-names></name><name><surname>Picot</surname><given-names>S</given-names></name><name><surname>Osborn</surname><given-names>DPJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Visual acuity in late adolescence and future psychosis risk in a cohort of 1 million men</article-title>. <source/>Schizophr Bull. Epub ahead of print 12 June 2018. DOI: <pub-id pub-id-type="doi">10.1093/schbul/sby084</pub-id>.</mixed-citation>
</ref>
<ref id="bibr44-2040622320905215">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schiffman</surname><given-names>J</given-names></name><name><surname>Maeda</surname><given-names>JA</given-names></name><name><surname>Hayashi</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>Premorbid childhood ocular alignment abnormalities and adult schizophrenia-spectrum disorder</article-title>. <source/>Schizophr Res
<year>2006</year>; <volume>81</volume>: <fpage>253</fpage>–<lpage>260</lpage>.<pub-id pub-id-type="pmid">16242918</pub-id></mixed-citation>
</ref>
<ref id="bibr45-2040622320905215">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kimhy</surname><given-names>D</given-names></name><name><surname>Corcoran</surname><given-names>C</given-names></name><name><surname>Harkavy-Friedman</surname><given-names>JM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Visual form perception: a comparison of individuals at high risk for psychosis, recent onset schizophrenia and chronic schizophrenia</article-title>. <source/>Schizophr Res
<year>2007</year>; <volume>97</volume>: <fpage>25</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">17884347</pub-id></mixed-citation>
</ref>
<ref id="bibr46-2040622320905215">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adams</surname><given-names>SA</given-names></name><name><surname>Nasrallah</surname><given-names>HA.</given-names></name></person-group>
<article-title>Multiple retinal anomalies in schizophrenia</article-title>. <source/>Schizophr Res
<year>2018</year>; <volume>195</volume>: <fpage>3</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">28755877</pub-id></mixed-citation>
</ref>
<ref id="bibr47-2040622320905215">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Viertio</surname><given-names>S</given-names></name><name><surname>Laitinen</surname><given-names>A</given-names></name><name><surname>Perala</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Visual impairment in persons with psychotic disorder</article-title>. <source/>Soc Psychiatry Psychiatr Epidemiol
<year>2007</year>; <volume>42</volume>: <fpage>902</fpage>–<lpage>908</lpage>.<pub-id pub-id-type="pmid">17846698</pub-id></mixed-citation>
</ref>
<ref id="bibr48-2040622320905215">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caldito</surname><given-names>NG</given-names></name><name><surname>Saidha</surname><given-names>S</given-names></name><name><surname>Sotirchos</surname><given-names>ES</given-names></name></person-group>, <etal>et al</etal>
<article-title>Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study</article-title>. <source/>Brain
<year>2018</year>; <volume>141</volume>: <fpage>3115</fpage>–<lpage>3129</lpage>.<pub-id pub-id-type="pmid">30312381</pub-id></mixed-citation>
</ref>
<ref id="bibr49-2040622320905215">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siger</surname><given-names>M</given-names></name><name><surname>Dziegielewski</surname><given-names>K</given-names></name><name><surname>Jasek</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy</article-title>. <source/>J Neurol
<year>2008</year>; <volume>255</volume>: <fpage>1555</fpage>–<lpage>1560</lpage>.<pub-id pub-id-type="pmid">18825432</pub-id></mixed-citation>
</ref>
<ref id="bibr50-2040622320905215">
<label>50</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paolillo</surname><given-names>A</given-names></name><name><surname>Pozzilli</surname><given-names>C</given-names></name><name><surname>Gasperini</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Brain atrophy in relapsing-remitting multiple sclerosis: relationship with ‘black holes’, disease duration and clinical disability</article-title>. <source/>J Neurol Sci
<year>2000</year>; <volume>174</volume>: <fpage>85</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">10727693</pub-id></mixed-citation>
</ref>
<ref id="bibr51-2040622320905215">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Double</surname><given-names>KL</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Kril</surname><given-names>JJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Topography of brain atrophy during normal aging and Alzheimer’s disease</article-title>. <source/>Neurobiol Aging
<year>1996</year>; <volume>17</volume>: <fpage>513</fpage>–<lpage>521</lpage>.<pub-id pub-id-type="pmid">8832624</pub-id></mixed-citation>
</ref>
<ref id="bibr52-2040622320905215">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>SC</given-names></name><name><surname>Magnani</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>Optical coherence tomography reveals retinal neuroaxonal thinning in frontotemporal dementia as in Alzheimer’s disease</article-title>. <source/>J Alzheimers Dis
<year>2017</year>; <volume>56</volume>: <fpage>1101</fpage>–<lpage>1107</lpage>.<pub-id pub-id-type="pmid">28106555</pub-id></mixed-citation>
</ref>
<ref id="bibr53-2040622320905215">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name></person-group>, <etal>et al</etal>
<article-title>Thinner changes of the retinal nerve fiber layer in patients with mild cognitive impairment and Alzheimer’s disease</article-title>. <source/>BMC Neurol
<year>2015</year>; <volume>15</volume>: <fpage>14</fpage>.<pub-id pub-id-type="pmid">25886372</pub-id></mixed-citation>
</ref>
<ref id="bibr54-2040622320905215">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>TL</given-names></name><name><surname>Sachdeva</surname><given-names>S</given-names></name><name><surname>Stahl</surname><given-names>SM.</given-names></name></person-group>
<article-title>Glutamate neurocircuitry: theoretical underpinnings in schizophrenia</article-title>. <source/>Front Pharmacol
<year>2012</year>; <volume>3</volume>: <fpage>195</fpage>.<pub-id pub-id-type="pmid">23189055</pub-id></mixed-citation>
</ref>
<ref id="bibr55-2040622320905215">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Snyder</surname><given-names>MA</given-names></name><name><surname>Gao</surname><given-names>WJ.</given-names></name></person-group>
<article-title>NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia</article-title>. <source/>Front Cell Neurosci
<year>2013</year>; <volume>7</volume>: <fpage>31</fpage>.<pub-id pub-id-type="pmid">23543703</pub-id></mixed-citation>
</ref>
<ref id="bibr56-2040622320905215">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lakhan</surname><given-names>SE</given-names></name><name><surname>Caro</surname><given-names>M</given-names></name><name><surname>Hadzimichalis</surname><given-names>N.</given-names></name></person-group>
<article-title>NMDA receptor activity in neuropsychiatric disorders</article-title>. <source/>Front Psychiatry
<year>2013</year>; <volume>4</volume>: <fpage>52</fpage>.<pub-id pub-id-type="pmid">23772215</pub-id></mixed-citation>
</ref>
<ref id="bibr57-2040622320905215">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goff</surname><given-names>DC</given-names></name><name><surname>Coyle</surname><given-names>JT.</given-names></name></person-group>
<article-title>The emerging role of glutamate in the pathophysiology and treatment of schizophrenia</article-title>. <source/>Am J Psychiatry
<year>2001</year>; <volume>158</volume>: <fpage>1367</fpage>–<lpage>1377</lpage>.<pub-id pub-id-type="pmid">11532718</pub-id></mixed-citation>
</ref>
<ref id="bibr58-2040622320905215">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deutsch</surname><given-names>SI</given-names></name><name><surname>Rosse</surname><given-names>RB</given-names></name><name><surname>Schwartz</surname><given-names>BL</given-names></name></person-group>, <etal>et al</etal>
<article-title>A revised excitotoxic hypothesis of schizophrenia: therapeutic implications</article-title>. <source/>Clin Neuropharmacol
<year>2001</year>; <volume>24</volume>: <fpage>43</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">11290881</pub-id></mixed-citation>
</ref>
<ref id="bibr59-2040622320905215">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sucher</surname><given-names>NJ</given-names></name><name><surname>Lipton</surname><given-names>SA</given-names></name><name><surname>Dreyer</surname><given-names>EB.</given-names></name></person-group>
<article-title>Molecular basis of glutamate toxicity in retinal ganglion cells</article-title>. <source/>Vision Res
<year>1997</year>; <volume>37</volume>: <fpage>3483</fpage>–<lpage>3493</lpage>.<pub-id pub-id-type="pmid">9425525</pub-id></mixed-citation>
</ref>
<ref id="bibr60-2040622320905215">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>XL</given-names></name><name><surname>Yang</surname><given-names>XL.</given-names></name></person-group>
<article-title>N-methyl-D-aspartate receptors in the retina</article-title>. <source/>Mol Neurobiol
<year>2006</year>; <volume>34</volume>: <fpage>163</fpage>–<lpage>179</lpage>.<pub-id pub-id-type="pmid">17308350</pub-id></mixed-citation>
</ref>
<ref id="bibr61-2040622320905215">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Samani</surname><given-names>NN</given-names></name><name><surname>Proudlock</surname><given-names>FA</given-names></name><name><surname>Siram</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal>
<article-title>Retinal layer abnormalities as biomarkers of schizophrenia. Schizophr Bull</article-title>
<year>2018</year>; <volume>44</volume>: <fpage>876</fpage>–<lpage>885</lpage>.</mixed-citation>
</ref>
<ref id="bibr62-2040622320905215">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>WW</given-names></name><name><surname>Tajunisah</surname><given-names>I</given-names></name><name><surname>Sharmilla</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>Retinal nerve fiber layer structure abnormalities in schizophrenia and its relationship to disease state: evidence from optical coherence tomography</article-title>. <source/>Invest Ophthalmol Vis Sci
<year>2013</year>; <volume>54</volume>: <fpage>7785</fpage>–<lpage>7792</lpage>.<pub-id pub-id-type="pmid">24135757</pub-id></mixed-citation>
</ref>
<ref id="bibr63-2040622320905215">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carlsson</surname><given-names>A.</given-names></name></person-group>
<article-title>The current status of the dopamine hypothesis of schizophrenia</article-title>. <source/>Neuropsychopharmacology
<year>1988</year>; <volume>1</volume>: <fpage>179</fpage>–<lpage>186</lpage>.<pub-id pub-id-type="pmid">3075131</pub-id></mixed-citation>
</ref>
<ref id="bibr64-2040622320905215">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brisch</surname><given-names>R</given-names></name><name><surname>Saniotis</surname><given-names>A</given-names></name><name><surname>Wolf</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue</article-title>. <source/>Front Psychiatry
<year>2014</year>; <volume>5</volume>: <fpage>47</fpage>.<pub-id pub-id-type="pmid">24904434</pub-id></mixed-citation>
</ref>
<ref id="bibr65-2040622320905215">
<label>65</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brandies</surname><given-names>R</given-names></name><name><surname>Yehuda</surname><given-names>S.</given-names></name></person-group>
<article-title>The possible role of retinal dopaminergic system in visual performance</article-title>. <source/>Neurosci Biobehav Rev
<year>2008</year>; <volume>32</volume>: <fpage>611</fpage>–<lpage>656</lpage>.<pub-id pub-id-type="pmid">18061262</pub-id></mixed-citation>
</ref>
<ref id="bibr66-2040622320905215">
<label>66</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Djamgoz</surname><given-names>MB</given-names></name><name><surname>Hankins</surname><given-names>MW</given-names></name><name><surname>Hirano</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Neurobiology of retinal dopamine in relation to degenerative states of the tissue</article-title>. <source/>Vision Res
<year>1997</year>; <volume>37</volume>: <fpage>3509</fpage>–<lpage>3529</lpage>.<pub-id pub-id-type="pmid">9425527</pub-id></mixed-citation>
</ref>
<ref id="bibr67-2040622320905215">
<label>67</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lavoie</surname><given-names>J</given-names></name><name><surname>Maziade</surname><given-names>M</given-names></name><name><surname>Hébert</surname><given-names>M.</given-names></name></person-group>
<article-title>The brain through the retina: The flash electroretinogram as a tool to investigate psychiatric disorders</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry
<year>2014</year>; <volume>48</volume>: <fpage>129</fpage>–<lpage>134</lpage>.<pub-id pub-id-type="pmid">24121062</pub-id></mixed-citation>
</ref>
<ref id="bibr68-2040622320905215">
<label>68</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Demmin</surname><given-names>DL</given-names></name><name><surname>Davis</surname><given-names>Q</given-names></name><name><surname>Roche</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Electroretinographic anomalies in schizophrenia</article-title>. <source/>J Abnorm Psychol
<year>2018</year>; <volume>127</volume>: <fpage>417</fpage>–<lpage>428</lpage>.<pub-id pub-id-type="pmid">29745706</pub-id></mixed-citation>
</ref>
<ref id="bibr69-2040622320905215">
<label>69</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moghimi</surname><given-names>P</given-names></name><name><surname>Torres Jimenez</surname><given-names>N</given-names></name><name><surname>McLoon</surname><given-names>LK</given-names></name></person-group>, <etal>et al</etal>
<article-title>Electoretinographic evidence of retinal ganglion cell-dependent function in schizophrenia</article-title>. <source/>Schizophr Res. Epub ahead of print 12 October 2019. DOI: <pub-id pub-id-type="doi">10.1016/j.schres.2019.09.005</pub-id>.</mixed-citation>
</ref>
<ref id="bibr70-2040622320905215">
<label>70</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hébert</surname><given-names>M</given-names></name><name><surname>Merette</surname><given-names>C</given-names></name><name><surname>Gagné</surname><given-names>AM</given-names></name></person-group>, <etal>et al</etal>
<article-title>The electroretinogram may differentiate schizophrenia from bipolar disorder</article-title>. <source/>Biol Psychiatry
<year>2020</year>
<volume>87</volume>: <fpage>263</fpage>–<lpage>270</lpage>.<pub-id pub-id-type="pmid">31443935</pub-id></mixed-citation>
</ref>
<ref id="bibr71-2040622320905215">
<label>71</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hébert</surname><given-names>M</given-names></name><name><surname>Merette</surname><given-names>C</given-names></name><name><surname>Paccalet</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>
<article-title>Light evoked potentials measured by electroretinogram may tap into the neurodevelopmental roots of schizophrenia</article-title>. <source/>Schizophr Res
<year>2015</year>; <volume>162</volume>: <fpage>294</fpage>–<lpage>295</lpage>.<pub-id pub-id-type="pmid">25579051</pub-id></mixed-citation>
</ref>
<ref id="bibr72-2040622320905215">
<label>72</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Celik</surname><given-names>M</given-names></name><name><surname>Kalenderoglu</surname><given-names>A</given-names></name><name><surname>Sevgi Karadag</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Decreases in ganglion cell layer and inner plexiform layer volumes correlate better with disease severity in schizophrenia patients than retinal nerve fiber layer thickness: findings from spectral optic coherence tomography</article-title>. <source/>Eur Psychiatry
<year>2016</year>; <volume>32</volume>: <fpage>9</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">26800301</pub-id></mixed-citation>
</ref>
<ref id="bibr73-2040622320905215">
<label>73</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ascaso</surname><given-names>FJ</given-names></name><name><surname>Cruz</surname><given-names>N</given-names></name><name><surname>Modrego</surname><given-names>PJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Retinal alterations in mild cognitive impairment and Alzheimer’s disease: an optical coherence tomography study</article-title>. <source/>J Neurol
<year>2014</year>; <volume>261</volume>: <fpage>1522</fpage>–<lpage>1530</lpage>.<pub-id pub-id-type="pmid">24846203</pub-id></mixed-citation>
</ref>
<ref id="bibr74-2040622320905215">
<label>74</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cabezon</surname><given-names>L</given-names></name><name><surname>Ascaso</surname><given-names>F</given-names></name><name><surname>Ramiro</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>
<article-title>Optical coherence tomography: a window into the brain of schizophrenic patients</article-title>. <source/>Acta Ophthalmologica
<year>2012</year>
<volume>90</volume>: <fpage>1755</fpage>.</mixed-citation>
</ref>
<ref id="bibr75-2040622320905215">
<label>75</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ascaso</surname><given-names>FJ</given-names></name><name><surname>Rodriguez-Jimenez</surname><given-names>R</given-names></name><name><surname>Cabezon</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>Retinal nerve fiber layer and macular thickness in patients with schizophrenia: influence of recent illness episodes</article-title>. <source/>Psychiatry Res
<year>2015</year>; <volume>229</volume>: <fpage>230</fpage>–<lpage>236</lpage>.<pub-id pub-id-type="pmid">26213374</pub-id></mixed-citation>
</ref>
<ref id="bibr76-2040622320905215">
<label>76</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kazakos</surname><given-names>CT</given-names></name><name><surname>Karageorgiou</surname><given-names>V.</given-names></name></person-group>
<article-title>Retinal changes in schizophrenia: a systematic review and meta-analysis based on individual participant data</article-title>. <source/>Schizophr Bull
<year>2020</year>; <volume>46</volume>: <fpage>27</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">31626695</pub-id></mixed-citation>
</ref>
<ref id="bibr77-2040622320905215">
<label>77</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>La Morgia</surname><given-names>C</given-names></name><name><surname>Di Vito</surname><given-names>L</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal>
<article-title>Patterns of retinal ganglion cell damage in neurodegenerative disorders: parvocellular vs magnocellular degeneration in optical coherence tomography studies</article-title>. <source/>Front Neurol
<year>2017</year>; <volume>8</volume>: <fpage>710</fpage>.<pub-id pub-id-type="pmid">29312131</pub-id></mixed-citation>
</ref>
<ref id="bibr78-2040622320905215">
<label>78</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Silverstein</surname><given-names>SM</given-names></name><name><surname>Paterno</surname><given-names>D</given-names></name><name><surname>Cherneski</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>Optical coherence tomography indices of structural retinal pathology in schizophrenia</article-title>. <source/>Psychol Med
<year>2018</year>; <volume>48</volume>: <fpage>2023</fpage>–<lpage>2033</lpage>.<pub-id pub-id-type="pmid">29233210</pub-id></mixed-citation>
</ref>
<ref id="bibr79-2040622320905215">
<label>79</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Topcu-Yilmaz</surname><given-names>P</given-names></name><name><surname>Aydin</surname><given-names>M</given-names></name><name><surname>Cetin Ilhan</surname><given-names>B.</given-names></name></person-group>
<article-title>Evaluation of retinal nerve fiber layer, macular, and choroidal thickness in schizophrenia: spectral optic coherence tomography findings</article-title>. <source/>Psychiat Clin Psych
<year>2019</year>; <volume>29</volume>: <fpage>28</fpage>–<lpage>33</lpage>.</mixed-citation>
</ref>
<ref id="bibr80-2040622320905215">
<label>80</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ascaso</surname><given-names>FJ</given-names></name><name><surname>Laura</surname><given-names>C</given-names></name><name><surname>Quintanilla</surname><given-names>MÁ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Retinal nerve fiber layer thickness measured by optical coherence tomography in patients with schizophrenia: a short report</article-title>. <source/>Eur J Psychiat
<year>2010</year>; <volume>24</volume>: <fpage>227</fpage>–<lpage>235</lpage>.</mixed-citation>
</ref>
<ref id="bibr81-2040622320905215">
<label>81</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>U</given-names></name><name><surname>Kucuk</surname><given-names>E</given-names></name><name><surname>Ulgen</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Retinal nerve fiber layer and macular thickness measurement in patients with schizophrenia</article-title>. <source/>Eur J Ophthalmol
<year>2016</year>; <volume>26</volume>: <fpage>375</fpage>–<lpage>378</lpage>.<pub-id pub-id-type="pmid">26742871</pub-id></mixed-citation>
</ref>
<ref id="bibr82-2040622320905215">
<label>82</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chu</surname><given-names>EM</given-names></name><name><surname>Kolappan</surname><given-names>M</given-names></name><name><surname>Barnes</surname><given-names>TR</given-names></name></person-group>, <etal>et al</etal>
<article-title>A window into the brain: an in vivo study of the retina in schizophrenia using optical coherence tomography</article-title>. <source/>Psychiatry Res
<year>2012</year>; <volume>203</volume>: <fpage>89</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">22917503</pub-id></mixed-citation>
</ref>
<ref id="bibr83-2040622320905215">
<label>83</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mehraban</surname><given-names>A</given-names></name><name><surname>Samimi</surname><given-names>SM</given-names></name><name><surname>Entezari</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Peripapillary retinal nerve fiber layer thickness in bipolar disorder</article-title>. <source/>Graefes Arch Clin Exp Ophthalmol
<year>2016</year>; <volume>254</volume>: <fpage>365</fpage>–<lpage>371</lpage>.<pub-id pub-id-type="pmid">25808660</pub-id></mixed-citation>
</ref>
<ref id="bibr84-2040622320905215">
<label>84</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalenderoglu</surname><given-names>A</given-names></name><name><surname>Sevgi-Karadag</surname><given-names>A</given-names></name><name><surname>Celik</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Can the retinal ganglion cell layer (GCL) volume be a new marker to detect neurodegeneration in bipolar disorder?</article-title>
<source/>Compr Psychiatry
<year>2016</year>; <volume>67</volume>: <fpage>66</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">27095337</pub-id></mixed-citation>
</ref>
<ref id="bibr85-2040622320905215">
<label>85</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khalil</surname><given-names>MA</given-names></name><name><surname>Saleh</surname><given-names>AA</given-names></name><name><surname>Gohar</surname><given-names>SM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Optical coherence tomography findings in patients with bipolar disorder</article-title>. <source/>J Affect Disord
<year>2017</year>; <volume>218</volume>: <fpage>115</fpage>–<lpage>122</lpage>.<pub-id pub-id-type="pmid">28472701</pub-id></mixed-citation>
</ref>
<ref id="bibr86-2040622320905215">
<label>86</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Polo</surname><given-names>V</given-names></name><name><surname>Satue</surname><given-names>M</given-names></name><name><surname>Gavin</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Ability of swept source OCT to detect retinal changes in patients with bipolar disorder</article-title>. <source/>Eye (Lond)
<year>2019</year>
<volume>33</volume>: <fpage>549</fpage>–<lpage>556</lpage>.<pub-id pub-id-type="pmid">30382239</pub-id></mixed-citation>
</ref>
<ref id="bibr87-2040622320905215">
<label>87</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yildiz</surname><given-names>M</given-names></name><name><surname>Alim</surname><given-names>S</given-names></name><name><surname>Batmaz</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Duration of the depressive episode is correlated with ganglion cell inner plexifrom layer and nasal retinal fiber layer thicknesses: optical coherence tomography findings in major depression</article-title>. <source/>Psychiatry Res Neuroimaging
<year>2016</year>; <volume>251</volume>: <fpage>60</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">27124425</pub-id></mixed-citation>
</ref>
<ref id="bibr88-2040622320905215">
<label>88</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sönmez</surname><given-names>I</given-names></name><name><surname>Kosger</surname><given-names>F</given-names></name><name><surname>Aykan</surname><given-names>U.</given-names></name></person-group>
<article-title>Retinal nerve fiber layer thickness measurement by spectral-domain optical coherence tomography in patients with major depressive disorder</article-title>. <source/>Noro Psikiyatr Ars
<year>2017</year>; <volume>54</volume>: <fpage>62</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">28566961</pub-id></mixed-citation>
</ref>
<ref id="bibr89-2040622320905215">
<label>89</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bresee</surname><given-names>LC</given-names></name><name><surname>Majumdar</surname><given-names>SR</given-names></name><name><surname>Patten</surname><given-names>SB</given-names></name></person-group>, <etal>et al</etal>
<article-title>Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study</article-title>. <source/>Schizophr Res
<year>2010</year>; <volume>117</volume>: <fpage>75</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">20080392</pub-id></mixed-citation>
</ref>
<ref id="bibr90-2040622320905215">
<label>90</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carney</surname><given-names>CP</given-names></name><name><surname>Jones</surname><given-names>L</given-names></name><name><surname>Woolson</surname><given-names>RF.</given-names></name></person-group>
<article-title>Medical comorbidity in women and men with schizophrenia: a population-based controlled study</article-title>. <source/>J Gen Intern Med
<year>2006</year>; <volume>21</volume>: <fpage>1133</fpage>–<lpage>1137</lpage>.<pub-id pub-id-type="pmid">17026726</pub-id></mixed-citation>
</ref>
<ref id="bibr91-2040622320905215">
<label>91</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Crump</surname><given-names>C</given-names></name><name><surname>Winkleby</surname><given-names>MA</given-names></name><name><surname>Sundquist</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study</article-title>. <source/>Am J Psychiatry
<year>2013</year>; <volume>170</volume>: <fpage>324</fpage>–<lpage>333</lpage>.<pub-id pub-id-type="pmid">23318474</pub-id></mixed-citation>
</ref>
<ref id="bibr92-2040622320905215">
<label>92</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hennekens</surname><given-names>CH</given-names></name><name><surname>Hennekens</surname><given-names>AR</given-names></name><name><surname>Hollar</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>Schizophrenia and increased risks of cardiovascular disease</article-title>. <source/>Am Heart J
<year>2005</year>; <volume>150</volume>: <fpage>1115</fpage>–<lpage>1121</lpage>.<pub-id pub-id-type="pmid">16338246</pub-id></mixed-citation>
</ref>
<ref id="bibr93-2040622320905215">
<label>93</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lahti</surname><given-names>M</given-names></name><name><surname>Tiihonen</surname><given-names>J</given-names></name><name><surname>Wildgust</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia</article-title>. <source/>Psychol Med
<year>2012</year>; <volume>42</volume>: <fpage>2275</fpage>–<lpage>2285</lpage>.<pub-id pub-id-type="pmid">22405504</pub-id></mixed-citation>
</ref>
<ref id="bibr94-2040622320905215">
<label>94</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>HC</given-names></name><name><surname>Hsiao</surname><given-names>FH</given-names></name><name><surname>Pfeiffer</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>An increased risk of stroke among young schizophrenia patients</article-title>. <source/>Schizophr Res
<year>2008</year>; <volume>101</volume>: <fpage>234</fpage>–<lpage>241</lpage>.<pub-id pub-id-type="pmid">18262395</pub-id></mixed-citation>
</ref>
<ref id="bibr95-2040622320905215">
<label>95</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>N</given-names></name><name><surname>Grover</surname><given-names>S</given-names></name><name><surname>Chakrabarti</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Metabolic syndrome in schizophrenia</article-title>. <source/>Indian J Psychol Med
<year>2013</year>; <volume>35</volume>: <fpage>227</fpage>–<lpage>240</lpage>.<pub-id pub-id-type="pmid">24249923</pub-id></mixed-citation>
</ref>
<ref id="bibr96-2040622320905215">
<label>96</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Hert</surname><given-names>M</given-names></name><name><surname>Schreurs</surname><given-names>V</given-names></name><name><surname>Vancampfort</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>Metabolic syndrome in people with schizophrenia: a review</article-title>. <source/>World Psychiatry
<year>2009</year>; <volume>8</volume>: <fpage>15</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">19293950</pub-id></mixed-citation>
</ref>
<ref id="bibr97-2040622320905215">
<label>97</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>PJ</given-names></name><name><surname>Rocha</surname><given-names>FL.</given-names></name></person-group>
<article-title>The prevalence of metabolic syndrome among psychiatric inpatients in Brazil</article-title>. <source/>Braz J Psychiatry
<year>2007</year>; <volume>29</volume>: <fpage>330</fpage>–<lpage>336</lpage>.<pub-id pub-id-type="pmid">18200397</pub-id></mixed-citation>
</ref>
<ref id="bibr98-2040622320905215">
<label>98</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kato</surname><given-names>MM</given-names></name><name><surname>Currier</surname><given-names>MB</given-names></name><name><surname>Gomez</surname><given-names>CM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia</article-title>. <source/>Prim Care Companion J Clin Psychiatry
<year>2004</year>; <volume>6</volume>: <fpage>74</fpage>–<lpage>77</lpage>.<pub-id pub-id-type="pmid">15254600</pub-id></mixed-citation>
</ref>
<ref id="bibr99-2040622320905215">
<label>99</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kumra</surname><given-names>S</given-names></name><name><surname>Oberstar</surname><given-names>JV</given-names></name><name><surname>Sikich</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia</article-title>. <source/>Schizophr Bull
<year>2008</year>; <volume>34</volume>: <fpage>60</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">17923452</pub-id></mixed-citation>
</ref>
<ref id="bibr100-2040622320905215">
<label>100</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Correll</surname><given-names>CU.</given-names></name></person-group>
<article-title>Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents</article-title>. <source/>J Clin Psychiatry
<year>2008</year>; <volume>69</volume>(<issue>Suppl. 4</issue>): <fpage>26</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">18533766</pub-id></mixed-citation>
</ref>
<ref id="bibr101-2040622320905215">
<label>101</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meier</surname><given-names>MH</given-names></name><name><surname>Shalev</surname><given-names>I</given-names></name><name><surname>Moffitt</surname><given-names>TE</given-names></name></person-group>, <etal>et al</etal>
<article-title>Microvascular abnormality in schizophrenia as shown by retinal imaging</article-title>. <source/>Am J Psychiatry
<year>2013</year>; <volume>170</volume>: <fpage>1451</fpage>–<lpage>1459</lpage>.<pub-id pub-id-type="pmid">24030514</pub-id></mixed-citation>
</ref>
<ref id="bibr102-2040622320905215">
<label>102</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meier</surname><given-names>MH</given-names></name><name><surname>Gillespie</surname><given-names>NA</given-names></name><name><surname>Hansell</surname><given-names>NK</given-names></name></person-group>, <etal>et al</etal>
<article-title>Retinal microvessels reflect familial vulnerability to psychotic symptoms: a comparison of twins discordant for psychotic symptoms and controls</article-title>. <source/>Schizophr Res
<year>2015</year>; <volume>164</volume>: <fpage>47</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">25694186</pub-id></mixed-citation>
</ref>
<ref id="bibr103-2040622320905215">
<label>103</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meier</surname><given-names>M</given-names></name><name><surname>Byrne</surname><given-names>E</given-names></name><name><surname>Martin</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>
<article-title>7.4 phenotypic and genetic associations between schizophrenia and retinal vessel diameter</article-title>. <source/>Schizophr Bull
<year>2018</year>; <volume>44</volume>: <fpage>S12</fpage> DOI: <pub-id pub-id-type="doi">10.1093/schbul/sby014.026</pub-id>.</mixed-citation>
</ref>
<ref id="bibr104-2040622320905215">
<label>104</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moises</surname><given-names>HW</given-names></name><name><surname>Wollschlager</surname><given-names>D</given-names></name><name><surname>Binder</surname><given-names>H.</given-names></name></person-group>
<article-title>Functional genomics indicate that schizophrenia may be an adult vascular-ischemic disorder</article-title>. <source/>Transl Psychiatry
<year>2015</year>; <volume>5</volume>: <fpage>e616</fpage>.<pub-id pub-id-type="pmid">26261884</pub-id></mixed-citation>
</ref>
<ref id="bibr105-2040622320905215">
<label>105</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whitford</surname><given-names>V</given-names></name><name><surname>O‘Driscoll</surname><given-names>GA</given-names></name><name><surname>Titone</surname><given-names>D.</given-names></name></person-group>
<article-title>Reading deficits in schizophrenia and their relationship to developmental dyslexia: a review</article-title>. <source/>Schizophr Res
<year>2018</year>; <volume>193</volume>: <fpage>11</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">28688740</pub-id></mixed-citation>
</ref>
<ref id="bibr106-2040622320905215">
<label>106</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khosravani</surname><given-names>N</given-names></name><name><surname>Goodarzi</surname><given-names>MA.</given-names></name></person-group>
<article-title>Patients with schizophrenia show deficits on spatial frequency doubling</article-title>. <source/>Vision Res
<year>2013</year>; <volume>93</volume>: <fpage>49</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">24140959</pub-id></mixed-citation>
</ref>
<ref id="bibr107-2040622320905215">
<label>107</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gracitelli</surname><given-names>CP</given-names></name><name><surname>Vaz</surname><given-names>de</given-names></name><name><surname>Lima</surname><given-names>FB</given-names></name><name><surname>Bressan</surname><given-names>RA</given-names></name></person-group>, <etal>et al</etal>
<article-title>Visual field loss in schizophrenia: evaluation of magnocellular pathway dysfunction in schizophrenic patients and their parents</article-title>. <source/>Clin Ophthalmol
<year>2013</year>; <volume>7</volume>: <fpage>1015</fpage>–<lpage>1021</lpage>.<pub-id pub-id-type="pmid">23807827</pub-id></mixed-citation>
</ref>
<ref id="bibr108-2040622320905215">
<label>108</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lima</surname><given-names>FB</given-names></name><name><surname>Gracitelli</surname><given-names>CP</given-names></name><name><surname>Paranhos Junior</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Evaluation of magnocellular pathway abnormalities in schizophrenia: a frequency doubling technology study and clinical implications</article-title>. <source/>Arq Bras Oftalmol
<year>2013</year>; <volume>76</volume>: <fpage>85</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="pmid">23828467</pub-id></mixed-citation>
</ref>
<ref id="bibr109-2040622320905215">
<label>109</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holzman</surname><given-names>PS</given-names></name><name><surname>Proctor</surname><given-names>LR</given-names></name><name><surname>Levy</surname><given-names>DL</given-names></name></person-group>, <etal>et al</etal>
<article-title>Eye-tracking dysfunctions in schizophrenic patients and their relatives. Arch Gen Psychiatry</article-title>
<year>1974</year>; <volume>31</volume>: <fpage>143</fpage>–<lpage>151</lpage>.</mixed-citation>
</ref>
<ref id="bibr110-2040622320905215">
<label>110</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Levy</surname><given-names>DL</given-names></name><name><surname>Sereno</surname><given-names>AB</given-names></name><name><surname>Gooding</surname><given-names>DC</given-names></name></person-group>, <etal>et al</etal>
<article-title>Eye tracking dysfunction in schizophrenia: characterization and pathophysiology</article-title>. <source/>Curr Top Behav Neurosci
<year>2010</year>; <volume>4</volume>: <fpage>311</fpage>–<lpage>347</lpage>.<pub-id pub-id-type="pmid">21312405</pub-id></mixed-citation>
</ref>
<ref id="bibr111-2040622320905215">
<label>111</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Slaghuis</surname><given-names>WL</given-names></name><name><surname>Bowling</surname><given-names>AC</given-names></name><name><surname>French</surname><given-names>RV.</given-names></name></person-group>
<article-title>Smooth-pursuit eye movement and directional motion-contrast sensitivity in schizophrenia</article-title>. <source/>Exp Brain Res
<year>2005</year>; <volume>166</volume>: <fpage>89</fpage>–<lpage>101</lpage>.<pub-id pub-id-type="pmid">16075296</pub-id></mixed-citation>
</ref>
<ref id="bibr112-2040622320905215">
<label>112</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keri</surname><given-names>S</given-names></name><name><surname>Kelemen</surname><given-names>O</given-names></name><name><surname>Janka</surname><given-names>Z</given-names></name></person-group>, <etal>et al</etal>
<article-title>Visual-perceptual dysfunctions are possible endophenotypes of schizophrenia: evidence from the psychophysical investigation of magnocellular and parvocellular pathways</article-title>. <source/>Neuropsychology
<year>2005</year>; <volume>19</volume>: <fpage>649</fpage>–<lpage>656</lpage>.<pub-id pub-id-type="pmid">16187883</pub-id></mixed-citation>
</ref>
<ref id="bibr113-2040622320905215">
<label>113</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Butler</surname><given-names>PD</given-names></name><name><surname>Javitt</surname><given-names>DC.</given-names></name></person-group>
<article-title>Early-stage visual processing deficits in schizophrenia</article-title>. <source/>Curr Opin Psychiatry
<year>2005</year>; <volume>18</volume>: <fpage>151</fpage>–<lpage>157</lpage>.<pub-id pub-id-type="pmid">16639168</pub-id></mixed-citation>
</ref>
<ref id="bibr114-2040622320905215">
<label>114</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anderson</surname><given-names>AJ</given-names></name><name><surname>Johnson</surname><given-names>CA.</given-names></name></person-group>
<article-title>Frequency-doubling technology perimetry</article-title>. <source/>Ophthalmol Clin North Am
<year>2003</year>; <volume>16</volume>: <fpage>213</fpage>–<lpage>225</lpage>.<pub-id pub-id-type="pmid">12809159</pub-id></mixed-citation>
</ref>
<ref id="bibr115-2040622320905215">
<label>115</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bedwell</surname><given-names>JS</given-names></name><name><surname>Miller</surname><given-names>LS</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Functional magnetic resonance imaging examination of the magnocellular visual pathway in nonpsychotic relatives of persons with schizophrenia</article-title>. <source/>Schizophr Res
<year>2004</year>; <volume>71</volume>: <fpage>509</fpage>–<lpage>510</lpage>.<pub-id pub-id-type="pmid">15474923</pub-id></mixed-citation>
</ref>
<ref id="bibr116-2040622320905215">
<label>116</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braus</surname><given-names>DF</given-names></name><name><surname>Weber-Fahr</surname><given-names>W</given-names></name><name><surname>Tost</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Sensory information processing in neuroleptic-naive first-episode schizophrenic patients: a functional magnetic resonance imaging study</article-title>. <source/>Arch Gen Psychiatry
<year>2002</year>; <volume>59</volume>: <fpage>696</fpage>-<lpage>701</lpage>.<pub-id pub-id-type="pmid">12150645</pub-id></mixed-citation>
</ref>
<ref id="bibr117-2040622320905215">
<label>117</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Hillyard</surname><given-names>SA</given-names></name><name><surname>Bickel</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Consequences of magnocellular dysfunction on processing attended information in schizophrenia</article-title>. <source/>Cereb Cortex
<year>2012</year>; <volume>22</volume>: <fpage>1282</fpage>–<lpage>1293</lpage>.<pub-id pub-id-type="pmid">21840846</pub-id></mixed-citation>
</ref>
<ref id="bibr118-2040622320905215">
<label>118</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Skottun</surname><given-names>BC</given-names></name><name><surname>Skoyles</surname><given-names>JR.</given-names></name></person-group>
<article-title>Contrast sensitivity and magnocellular functioning in schizophrenia</article-title>. <source/>Vision Research
<year>2007</year>; <volume>47</volume>: <fpage>2923</fpage>–<lpage>2933</lpage>.<pub-id pub-id-type="pmid">17825350</pub-id></mixed-citation>
</ref>
<ref id="bibr119-2040622320905215">
<label>119</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Richards</surname><given-names>W</given-names></name><name><surname>Felton</surname><given-names>TB.</given-names></name></person-group>
<article-title>Spatial frequency doubling: retinal or central?</article-title>
<source/>Vision Res
<year>1973</year>; <volume>13</volume>: <fpage>2129</fpage>–<lpage>2137</lpage>.<pub-id pub-id-type="pmid">4763526</pub-id></mixed-citation>
</ref>
<ref id="bibr120-2040622320905215">
<label>120</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>White</surname><given-names>AJ</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Swanson</surname><given-names>WH</given-names></name></person-group>, <etal>et al</etal>
<article-title>An examination of physiological mechanisms underlying the frequency-doubling illusion</article-title>. <source/>Invest Ophthalmol Vis Sci
<year>2002</year>; <volume>43</volume>: <fpage>3590</fpage>–<lpage>3599</lpage>.<pub-id pub-id-type="pmid">12407172</pub-id></mixed-citation>
</ref>
<ref id="bibr121-2040622320905215">
<label>121</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jung</surname><given-names>KI</given-names></name><name><surname>Kim</surname><given-names>EK</given-names></name><name><surname>Park</surname><given-names>CK.</given-names></name></person-group>
<article-title>Usefulness of frequency doubling technology perimetry 24-2 in glaucoma with parafoveal scotoma</article-title>. <source/>Medicine (Baltimore)
<year>2017</year>; <volume>96</volume>: <fpage>e6855</fpage>.<pub-id pub-id-type="pmid">28614218</pub-id></mixed-citation>
</ref>
<ref id="bibr122-2040622320905215">
<label>122</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lim</surname><given-names>JKH</given-names></name><name><surname>Li</surname><given-names>Q-X</given-names></name><name><surname>He</surname><given-names>Z</given-names></name></person-group>, <etal>et al</etal>
<article-title>The eye as a biomarker for Alzheimer’s disease</article-title>. <source/>Front Neurosci
<year>2016</year>; <volume>10</volume>
<fpage>536</fpage>.<pub-id pub-id-type="pmid">27909396</pub-id></mixed-citation>
</ref>
<ref id="bibr123-2040622320905215">
<label>123</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vita</surname><given-names>A</given-names></name><name><surname>De Peri</surname><given-names>L</given-names></name><name><surname>Deste</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies</article-title>. <source/>Transl Psychiatry
<year>2012</year>; <volume>2</volume>: <fpage>e190</fpage>.<pub-id pub-id-type="pmid">23168990</pub-id></mixed-citation>
</ref>
<ref id="bibr124-2040622320905215">
<label>124</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muller</surname><given-names>N</given-names></name><name><surname>Weidinger</surname><given-names>E</given-names></name><name><surname>Leitner</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal>
<article-title>The role of inflammation in schizophrenia</article-title>. <source/>Front Neurosci
<year>2015</year>; <volume>9</volume>: <fpage>372</fpage>.<pub-id pub-id-type="pmid">26539073</pub-id></mixed-citation>
</ref>
<ref id="bibr125-2040622320905215">
<label>125</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haupt</surname><given-names>DW.</given-names></name></person-group>
<article-title>Differential metabolic effects of antipsychotic treatments</article-title>. <source/>Eur Neuropsychopharmacol
<year>2006</year>; <volume>16</volume>(<issue>Suppl. 3</issue>): <fpage>S149</fpage>–<lpage>S155</lpage>.<pub-id pub-id-type="pmid">16872808</pub-id></mixed-citation>
</ref>
<ref id="bibr126-2040622320905215">
<label>126</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tourjman</surname><given-names>V</given-names></name><name><surname>Kouassi</surname><given-names>E</given-names></name><name><surname>Koue</surname><given-names>ME</given-names></name></person-group>, <etal>et al</etal>
<article-title>Antipsychotics’ effects on blood levels of cytokines in schizophrenia: a meta-analysis</article-title>. <source/>Schizophr Res
<year>2013</year>; <volume>151</volume>: <fpage>43</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">24200418</pub-id></mixed-citation>
</ref>
<ref id="bibr127-2040622320905215">
<label>127</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lindstrom</surname><given-names>E</given-names></name><name><surname>Wieselgren</surname><given-names>IM</given-names></name><name><surname>von Knorring</surname><given-names>L.</given-names></name></person-group>
<article-title>Interrater reliability of the structured clinical interview for the positive and negative syndrome scale for schizophrenia</article-title>. <source/>Acta Psychiatr Scand
<year>1994</year>; <volume>89</volume>: <fpage>192</fpage>–<lpage>195</lpage>.<pub-id pub-id-type="pmid">8178678</pub-id></mixed-citation>
</ref>
<ref id="bibr128-2040622320905215">
<label>128</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andreasen</surname><given-names>NC.</given-names></name></person-group>
<article-title>The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations</article-title>. <source/>Br J Psychiatry Suppl
<year>1989</year>; <volume>155</volume>: <fpage>49</fpage>–<lpage>52</lpage>.</mixed-citation>
</ref>
<ref id="bibr129-2040622320905215">
<label>129</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Busner</surname><given-names>J</given-names></name><name><surname>Targum</surname><given-names>SD</given-names></name></person-group>
<article-title>The clinical global impressions scale: applying a research tool in clinical practice</article-title>. <source/>Psychiatry (Edgmont)
<year>2007</year>; <volume>4</volume>: <fpage>28</fpage>–<lpage>37</lpage>.</mixed-citation>
</ref>
<ref id="bibr130-2040622320905215">
<label>130</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jaaro-Peled</surname><given-names>H</given-names></name><name><surname>Ayhan</surname><given-names>Y</given-names></name><name><surname>Pletnikov</surname><given-names>MV</given-names></name></person-group>, <etal>et al</etal>
<article-title>Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models</article-title>. <source/>Schizophr Bull
<year>2010</year>; <volume>36</volume>: <fpage>301</fpage>–<lpage>313</lpage>.<pub-id pub-id-type="pmid">19903746</pub-id></mixed-citation>
</ref>
<ref id="bibr131-2040622320905215">
<label>131</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>CA</given-names></name><name><surname>Watson</surname><given-names>DJ</given-names></name><name><surname>Fone</surname><given-names>KC.</given-names></name></person-group>
<article-title>Animal models of schizophrenia</article-title>. <source/>Br J Pharmacol
<year>2011</year>; <volume>164</volume>: <fpage>1162</fpage>–<lpage>1194</lpage>.<pub-id pub-id-type="pmid">21449915</pub-id></mixed-citation>
</ref>
<ref id="bibr132-2040622320905215">
<label>132</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carpenter</surname><given-names>WT</given-names></name><name><surname>Koenig</surname><given-names>JI.</given-names></name></person-group>
<article-title>The evolution of drug development in schizophrenia: past issues and future opportunities</article-title>. <source/>Neuropsychopharmacology
<year>2008</year>; <volume>33</volume>: <fpage>2061</fpage>–<lpage>2079</lpage>.<pub-id pub-id-type="pmid">18046305</pub-id></mixed-citation>
</ref>
<ref id="bibr133-2040622320905215">
<label>133</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bodis-Wollner</surname><given-names>I.</given-names></name></person-group>
<article-title>Visual deficits related to dopamine deficiency in experimental animals and Parkinson’s disease patients</article-title>. <source/>Trends Neurosci
<year>1990</year>; <volume>13</volume>: <fpage>296</fpage>–<lpage>302</lpage>.<pub-id pub-id-type="pmid">1695407</pub-id></mixed-citation>
</ref>
<ref id="bibr134-2040622320905215">
<label>134</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Navari</surname><given-names>S</given-names></name><name><surname>Dazzan</surname><given-names>P.</given-names></name></person-group>
<article-title>Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings</article-title>. <source/>Psychol Med
<year>2009</year>; <volume>39</volume>: <fpage>1763</fpage>–<lpage>1777</lpage>.<pub-id pub-id-type="pmid">19338710</pub-id></mixed-citation>
</ref>
<ref id="bibr135-2040622320905215">
<label>135</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mudo</surname><given-names>G</given-names></name><name><surname>Belluardo</surname><given-names>N</given-names></name><name><surname>Fuxe</surname><given-names>K.</given-names></name></person-group>
<article-title>Nicotinic receptor agonists as neuroprotective/neurotrophic drugs.Progress in molecular mechanisms</article-title>. <source/>J Neural Transm (Vienna) <year>2007</year>; <volume>114</volume>: <fpage>135</fpage>–<lpage>147</lpage>.<pub-id pub-id-type="pmid">16906354</pub-id></mixed-citation>
</ref>
<ref id="bibr136-2040622320905215">
<label>136</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>N</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>
<article-title>Additive effect of cigarette smoking on gray matter abnormalities in schizophrenia</article-title>. <source/>Schizophr Bull
<year>2018</year>; <volume>44</volume>: <fpage>535</fpage>–<lpage>541</lpage>.<pub-id pub-id-type="pmid">29036371</pub-id></mixed-citation>
</ref>
<ref id="bibr137-2040622320905215">
<label>137</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moschos</surname><given-names>MM</given-names></name><name><surname>Nitoda</surname><given-names>E</given-names></name><name><surname>Laios</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>The impact of chronic tobacco smoking on retinal and choroidal thickness in Greek population</article-title>. <source/>Oxid Med Cell Longev
<year>2016</year>; <volume>2016</volume>: <fpage>2905789</fpage>.<pub-id pub-id-type="pmid">26885247</pub-id></mixed-citation>
</ref>
<ref id="bibr138-2040622320905215">
<label>138</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Merikangas</surname><given-names>KR</given-names></name><name><surname>Jin</surname><given-names>R</given-names></name><name><surname>He</surname><given-names>JP</given-names></name></person-group>, <etal>et al</etal>
<article-title>Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative</article-title>. <source/>Arch Gen Psychiatry
<year>2011</year>; <volume>68</volume>: <fpage>241</fpage>–<lpage>251</lpage>.<pub-id pub-id-type="pmid">21383262</pub-id></mixed-citation>
</ref>
<ref id="bibr139-2040622320905215">
<label>139</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Akiskal</surname><given-names>HS</given-names></name><name><surname>Bourgeois</surname><given-names>ML</given-names></name><name><surname>Angst</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders</article-title>. <source/>J Affect Disord
<year>2000</year>; <volume>59</volume>(<issue>Suppl. 1</issue>): <fpage>S5</fpage>–<lpage>S30</lpage>.<pub-id pub-id-type="pmid">11121824</pub-id></mixed-citation>
</ref>
<ref id="bibr140-2040622320905215">
<label>140</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>DJ</given-names></name><name><surname>Griffiths</surname><given-names>E</given-names></name><name><surname>Kelly</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Unrecognised bipolar disorder in primary care patients with depression</article-title>. <source/>Br J Psychiatry
<year>2011</year>; <volume>199</volume>: <fpage>49</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">21292927</pub-id></mixed-citation>
</ref>
<ref id="bibr141-2040622320905215">
<label>141</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hughes</surname><given-names>T</given-names></name><name><surname>Cardno</surname><given-names>A</given-names></name><name><surname>West</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Unrecognised bipolar disorder among UK primary care patients prescribed antidepressants: an observational study</article-title>. <source/>Br J Gen Pract
<year>2016</year>; <volume>66</volume>: <fpage>e71</fpage>–<lpage>e77</lpage>.<pub-id pub-id-type="pmid">26740604</pub-id></mixed-citation>
</ref>
<ref id="bibr142-2040622320905215">
<label>142</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chengappa</surname><given-names>KN</given-names></name><name><surname>Kupfer</surname><given-names>DJ</given-names></name><name><surname>Frank</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>
<article-title>Relationship of birth cohort and early age at onset of illness in a bipolar disorder case registry</article-title>. <source/>Am J Psychiatry
<year>2003</year>; <volume>160</volume>: <fpage>1636</fpage>–<lpage>1642</lpage>.<pub-id pub-id-type="pmid">12944339</pub-id></mixed-citation>
</ref>
<ref id="bibr143-2040622320905215">
<label>143</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Geller</surname><given-names>B</given-names></name><name><surname>Tillman</surname><given-names>R</given-names></name><name><surname>Craney</surname><given-names>JL</given-names></name></person-group>, <etal>et al</etal>
<article-title>Four-year prospective outcome and natural history of mania in children with a prepubertal and early adolescent bipolar disorder phenotype</article-title>. <source/>Arch Gen Psychiatry
<year>2004</year>; <volume>61</volume>: <fpage>459</fpage>–<lpage>467</lpage>.<pub-id pub-id-type="pmid">15123490</pub-id></mixed-citation>
</ref>
<ref id="bibr144-2040622320905215">
<label>144</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perlis</surname><given-names>RH</given-names></name><name><surname>Miyahara</surname><given-names>S</given-names></name><name><surname>Marangell</surname><given-names>LB</given-names></name></person-group>, <etal>et al</etal>
<article-title>Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD)</article-title>. <source/>Biol Psychiatry
<year>2004</year>; <volume>55</volume>: <fpage>875</fpage>–<lpage>881</lpage>.<pub-id pub-id-type="pmid">15110730</pub-id></mixed-citation>
</ref>
<ref id="bibr145-2040622320905215">
<label>145</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Strober</surname><given-names>M</given-names></name><name><surname>Schmidt-Lackner</surname><given-names>S</given-names></name><name><surname>Freeman</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Recovery and relapse in adolescents with bipolar affective illness: a five-year naturalistic, prospective follow-up</article-title>. <source/>J Am Acad Child Adolesc Psychiatry
<year>1995</year>; <volume>34</volume>: <fpage>724</fpage>–<lpage>731</lpage>.<pub-id pub-id-type="pmid">7608045</pub-id></mixed-citation>
</ref>
<ref id="bibr146-2040622320905215">
<label>146</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Birmaher</surname><given-names>B</given-names></name><name><surname>Axelson</surname><given-names>D</given-names></name><name><surname>Strober</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Clinical course of children and adolescents with bipolar spectrum disorders</article-title>. <source/>Arch Gen Psychiatry
<year>2006</year>; <volume>63</volume>: <fpage>175</fpage>–<lpage>183</lpage>.<pub-id pub-id-type="pmid">16461861</pub-id></mixed-citation>
</ref>
<ref id="bibr147-2040622320905215">
<label>147</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Geller</surname><given-names>B</given-names></name><name><surname>Craney</surname><given-names>JL</given-names></name><name><surname>Bolhofner</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>Two-year prospective follow-up of children with a prepubertal and early adolescent bipolar disorder phenotype</article-title>. <source/>Am J Psychiatry
<year>2002</year>; <volume>159</volume>: <fpage>927</fpage>–<lpage>933</lpage>.<pub-id pub-id-type="pmid">12042179</pub-id></mixed-citation>
</ref>
<ref id="bibr148-2040622320905215">
<label>148</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moorhead</surname><given-names>TW</given-names></name><name><surname>McKirdy</surname><given-names>J</given-names></name><name><surname>Sussmann</surname><given-names>JE</given-names></name></person-group>, <etal>et al</etal>
<article-title>Progressive gray matter loss in patients with bipolar disorder</article-title>. <source/>Biol Psychiatry
<year>2007</year>; <volume>62</volume>: <fpage>894</fpage>–<lpage>900</lpage>.<pub-id pub-id-type="pmid">17617385</pub-id></mixed-citation>
</ref>
<ref id="bibr149-2040622320905215">
<label>149</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vita</surname><given-names>A</given-names></name><name><surname>De Peri</surname><given-names>L</given-names></name><name><surname>Sacchetti</surname><given-names>E.</given-names></name></person-group>
<article-title>Gray matter, white matter, brain, and intracranial volumes in first-episode bipolar disorder: a meta-analysis of magnetic resonance imaging studies</article-title>. <source/>Bipolar Disord
<year>2009</year>; <volume>11</volume>: <fpage>807</fpage>–<lpage>814</lpage>.<pub-id pub-id-type="pmid">19922551</pub-id></mixed-citation>
</ref>
<ref id="bibr150-2040622320905215">
<label>150</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garcia-Martin</surname><given-names>E</given-names></name><name><surname>Gavin</surname><given-names>A</given-names></name><name><surname>Garcia-Campayo</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Visual function and retinal changes in patients with bipolar disorder</article-title>. <source/>Retina
<year>2019</year>; <volume>39</volume>: <fpage>2012</fpage>–<lpage>2021</lpage>.<pub-id pub-id-type="pmid">30015763</pub-id></mixed-citation>
</ref>
<ref id="bibr151-2040622320905215">
<label>151</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garcia-Martin</surname><given-names>E</given-names></name><name><surname>Larrosa</surname><given-names>JM</given-names></name><name><surname>Polo</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal>
<article-title>Distribution of retinal layer atrophy in patients with Parkinson disease and association with disease severity and duration</article-title>. <source/>Am J Ophthalmol
<year>2014</year>; <volume>157</volume>: <fpage>470</fpage>–<lpage>478.e472</lpage>.<pub-id pub-id-type="pmid">24315296</pub-id></mixed-citation>
</ref>
<ref id="bibr152-2040622320905215">
<label>152</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hebert</surname><given-names>M</given-names></name><name><surname>Gagne</surname><given-names>AM</given-names></name><name><surname>Paradis</surname><given-names>ME</given-names></name></person-group>, <etal>et al</etal>
<article-title>Retinal response to light in young nonaffected offspring at high genetic risk of neuropsychiatric brain disorders</article-title>. <source/>Biol Psychiatry
<year>2010</year>; <volume>67</volume>: <fpage>270</fpage>–<lpage>274</lpage>.<pub-id pub-id-type="pmid">19833322</pub-id></mixed-citation>
</ref>
<ref id="bibr153-2040622320905215">
<label>153</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maziade</surname><given-names>M</given-names></name><name><surname>Paccalet</surname><given-names>T</given-names></name><name><surname>Gagné</surname><given-names>A-M</given-names></name></person-group>, <etal>et al</etal>
<article-title>7.2 electroretinographic abnormalities seen in patients affected by schizophrenia or bipolar disorder are detectable early in children born to an affected parent: implications for the staging of risk status in childhood-adolesence</article-title>. <source/>Schizophr Bull
<year>2018</year>; <volume>44</volume>: <fpage>S11</fpage>.</mixed-citation>
</ref>
<ref id="bibr154-2040622320905215">
<label>154</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Levitan</surname><given-names>RD.</given-names></name></person-group>
<article-title>The chronobiology and neurobiology of winter seasonal affective disorder</article-title>. <source/>Dialogues Clin Neurosci
<year>2007</year>; <volume>9</volume>: <fpage>315</fpage>–<lpage>324</lpage>.<pub-id pub-id-type="pmid">17969868</pub-id></mixed-citation>
</ref>
<ref id="bibr155-2040622320905215">
<label>155</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dunlop</surname><given-names>BW</given-names></name><name><surname>Nemeroff</surname><given-names>CB.</given-names></name></person-group>
<article-title>The role of dopamine in the pathophysiology of depression</article-title>. <source/>Arch Gen Psychiatry
<year>2007</year>; <volume>64</volume>: <fpage>327</fpage>–<lpage>337</lpage>.<pub-id pub-id-type="pmid">17339521</pub-id></mixed-citation>
</ref>
<ref id="bibr156-2040622320905215">
<label>156</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJ</given-names></name><name><surname>Lopez</surname><given-names>AD.</given-names></name></person-group>
<article-title>Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study</article-title>. <source/>Lancet
<year>1997</year>; <volume>349</volume>: <fpage>1498</fpage>–<lpage>1504</lpage>.<pub-id pub-id-type="pmid">9167458</pub-id></mixed-citation>
</ref>
<ref id="bibr157-2040622320905215">
<label>157</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Friedrich</surname><given-names>MJ</given-names></name></person-group>
<article-title>Depression is the leading cause of disability around the world</article-title>. <source/>JAMA
<year>2017</year>; <volume>317</volume>: <fpage>1517</fpage>.</mixed-citation>
</ref>
<ref id="bibr158-2040622320905215">
<label>158</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kendler</surname><given-names>KS</given-names></name><name><surname>Kuhn</surname><given-names>J</given-names></name><name><surname>Prescott</surname><given-names>CA.</given-names></name></person-group>
<article-title>The interrelationship of neuroticism, sex, and stressful life events in the prediction of episodes of major depression</article-title>. <source/>Am J Psychiatry
<year>2004</year>; <volume>161</volume>: <fpage>631</fpage>–<lpage>636</lpage>.<pub-id pub-id-type="pmid">15056508</pub-id></mixed-citation>
</ref>
<ref id="bibr159-2040622320905215">
<label>159</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haavik</surname><given-names>J</given-names></name><name><surname>Blau</surname><given-names>N</given-names></name><name><surname>Thony</surname><given-names>B.</given-names></name></person-group>
<article-title>Mutations in human monoamine-related neurotransmitter pathway genes</article-title>. <source/>Hum Mutat
<year>2008</year>; <volume>29</volume>: <fpage>891</fpage>–<lpage>902</lpage>.<pub-id pub-id-type="pmid">18444257</pub-id></mixed-citation>
</ref>
<ref id="bibr160-2040622320905215">
<label>160</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jabbi</surname><given-names>M</given-names></name><name><surname>Korf</surname><given-names>J</given-names></name><name><surname>Ormel</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Investigating the molecular basis of major depressive disorder etiology: a functional convergent genetic approach</article-title>. <source/>Ann N Y Acad Sci
<year>2008</year>; <volume>1148</volume>: <fpage>42</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">19120090</pub-id></mixed-citation>
</ref>
<ref id="bibr161-2040622320905215">
<label>161</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Savitz</surname><given-names>JB</given-names></name><name><surname>Drevets</surname><given-names>WC.</given-names></name></person-group>
<article-title>Imaging phenotypes of major depressive disorder: genetic correlates</article-title>. <source/>Neuroscience
<year>2009</year>; <volume>164</volume>: <fpage>300</fpage>–<lpage>330</lpage>.<pub-id pub-id-type="pmid">19358877</pub-id></mixed-citation>
</ref>
<ref id="bibr162-2040622320905215">
<label>162</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Bullard</surname><given-names>KM</given-names></name><name><surname>Cotch</surname><given-names>MF</given-names></name></person-group>, <etal>et al</etal>
<article-title>Association between depression and functional vision loss in persons 20 years of age or older in the United States, NHANES 2005-2008</article-title>. <source/>JAMA Ophthalmol
<year>2013</year>; <volume>131</volume>: <fpage>573</fpage>–<lpage>581</lpage>.<pub-id pub-id-type="pmid">23471505</pub-id></mixed-citation>
</ref>
<ref id="bibr163-2040622320905215">
<label>163</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muller</surname><given-names>N</given-names></name><name><surname>Schwarz</surname><given-names>MJ.</given-names></name></person-group>
<article-title>The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression</article-title>. <source/>Mol Psychiatry
<year>2007</year>; <volume>12</volume>: <fpage>988</fpage>–<lpage>1000</lpage>.<pub-id pub-id-type="pmid">17457312</pub-id></mixed-citation>
</ref>
<ref id="bibr164-2040622320905215">
<label>164</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Euesden</surname><given-names>J</given-names></name><name><surname>Danese</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>CM</given-names></name></person-group>, <etal>et al</etal>
<article-title>A bidirectional relationship between depression and the autoimmune disorders - New perspectives from the National Child Development Study</article-title>. <source/>PLoS One
<year>2017</year>; <volume>12</volume>: <fpage>e0173015</fpage>.<pub-id pub-id-type="pmid">28264010</pub-id></mixed-citation>
</ref>
<ref id="bibr165-2040622320905215">
<label>165</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bruce</surname><given-names>TO.</given-names></name></person-group>
<article-title>Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications</article-title>. <source/>Curr Psychiatry Rep
<year>2008</year>; <volume>10</volume>: <fpage>258</fpage>–<lpage>264</lpage>.<pub-id pub-id-type="pmid">18652795</pub-id></mixed-citation>
</ref>
<ref id="bibr166-2040622320905215">
<label>166</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pryce</surname><given-names>CR</given-names></name><name><surname>Fontana</surname><given-names>A.</given-names></name></person-group>
<article-title>Depression in autoimmune diseases</article-title>. <source/>Curr Top Behav Neurosci
<year>2017</year>; <volume>31</volume>: <fpage>139</fpage>–<lpage>154</lpage>.<pub-id pub-id-type="pmid">27221625</pub-id></mixed-citation>
</ref>
<ref id="bibr167-2040622320905215">
<label>167</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heneka</surname><given-names>MT</given-names></name><name><surname>Carson</surname><given-names>MJ</given-names></name><name><surname>El Khoury</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Neuroinflammation in Alzheimer’s disease</article-title>. <source/>Lancet Neurol
<year>2015</year>; <volume>14</volume>: <fpage>388</fpage>–<lpage>405</lpage>.<pub-id pub-id-type="pmid">25792098</pub-id></mixed-citation>
</ref>
<ref id="bibr168-2040622320905215">
<label>168</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ardura-Fabregat</surname><given-names>A</given-names></name><name><surname>Boddeke</surname><given-names>E</given-names></name><name><surname>Boza-Serrano</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Targeting neuroinflammation to treat Alzheimer’s disease</article-title>. <source/>CNS Drugs
<year>2017</year>; <volume>31</volume>: <fpage>1057</fpage>–<lpage>1082</lpage>.<pub-id pub-id-type="pmid">29260466</pub-id></mixed-citation>
</ref>
<ref id="bibr169-2040622320905215">
<label>169</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>ST</given-names></name><name><surname>Clarke</surname><given-names>JR</given-names></name><name><surname>Bomfim</surname><given-names>TR</given-names></name></person-group>, <etal>et al</etal>
<article-title>Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer’s disease</article-title>. <source/>Alzheimers Dement
<year>2014</year>; <volume>10</volume>: <fpage>S76</fpage>–<lpage>S83</lpage>.<pub-id pub-id-type="pmid">24529528</pub-id></mixed-citation>
</ref>
<ref id="bibr170-2040622320905215">
<label>170</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Querfurth</surname><given-names>HW</given-names></name><name><surname>LaFerla</surname><given-names>FM.</given-names></name></person-group>
<article-title>Alzheimer’s disease</article-title>. <source/>N Engl J Med
<year>2010</year>; <volume>362</volume>: <fpage>329</fpage>–<lpage>344</lpage>.<pub-id pub-id-type="pmid">20107219</pub-id></mixed-citation>
</ref>
<ref id="bibr171-2040622320905215">
<label>171</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Geerlings</surname><given-names>MI</given-names></name><name><surname>den Heijer</surname><given-names>T</given-names></name><name><surname>Koudstaal</surname><given-names>PJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease</article-title>. <source/>Neurology
<year>2008</year>; <volume>70</volume>: <fpage>1258</fpage>–<lpage>1264</lpage>.<pub-id pub-id-type="pmid">18391157</pub-id></mixed-citation>
</ref>
<ref id="bibr172-2040622320905215">
<label>172</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barnes</surname><given-names>DE</given-names></name><name><surname>Yaffe</surname><given-names>K</given-names></name><name><surname>Byers</surname><given-names>AL</given-names></name></person-group>, <etal>et al</etal>
<article-title>Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia</article-title>. <source/>Arch Gen Psychiatry
<year>2012</year>; <volume>69</volume>: <fpage>493</fpage>–<lpage>498</lpage>.<pub-id pub-id-type="pmid">22566581</pub-id></mixed-citation>
</ref>
<ref id="bibr173-2040622320905215">
<label>173</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Green</surname><given-names>RC</given-names></name><name><surname>Cupples</surname><given-names>LA</given-names></name><name><surname>Kurz</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Depression as a risk factor for Alzheimer disease: the MIRAGE Study</article-title>. <source/>Arch Neurol
<year>2003</year>; <volume>60</volume>: <fpage>753</fpage>–<lpage>759</lpage>.<pub-id pub-id-type="pmid">12756140</pub-id></mixed-citation>
</ref>
<ref id="bibr174-2040622320905215">
<label>174</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ownby</surname><given-names>RL</given-names></name><name><surname>Crocco</surname><given-names>E</given-names></name><name><surname>Acevedo</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis</article-title>. <source/>Arch Gen Psychiatry
<year>2006</year>; <volume>63</volume>: <fpage>530</fpage>–<lpage>538</lpage>.<pub-id pub-id-type="pmid">16651510</pub-id></mixed-citation>
</ref>
<ref id="bibr175-2040622320905215">
<label>175</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Speck</surname><given-names>CE</given-names></name><name><surname>Kukull</surname><given-names>WA</given-names></name><name><surname>Brenner</surname><given-names>DE</given-names></name></person-group>, <etal>et al</etal>
<article-title>History of depression as a risk factor for Alzheimer’s disease</article-title>. <source/>Epidemiology
<year>1995</year>; <volume>6</volume>: <fpage>366</fpage>–<lpage>369</lpage>.<pub-id pub-id-type="pmid">7548342</pub-id></mixed-citation>
</ref>
<ref id="bibr176-2040622320905215">
<label>176</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanacora</surname><given-names>G</given-names></name><name><surname>Banasr</surname><given-names>M.</given-names></name></person-group>
<article-title>From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders</article-title>. <source/>Biol Psychiatry
<year>2013</year>; <volume>73</volume>: <fpage>1172</fpage>–<lpage>1179</lpage>.<pub-id pub-id-type="pmid">23726152</pub-id></mixed-citation>
</ref>
<ref id="bibr177-2040622320905215">
<label>177</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Czeh</surname><given-names>B</given-names></name><name><surname>Lucassen</surname><given-names>PJ.</given-names></name></person-group>
<article-title>What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated?</article-title>
<source/>Eur Arch Psychiatry Clin Neurosci
<year>2007</year>; <volume>257</volume>: <fpage>250</fpage>–<lpage>260</lpage>.<pub-id pub-id-type="pmid">17401728</pub-id></mixed-citation>
</ref>
<ref id="bibr178-2040622320905215">
<label>178</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Campbell</surname><given-names>S</given-names></name><name><surname>MacQueen</surname><given-names>G.</given-names></name></person-group>
<article-title>An update on regional brain volume differences associated with mood disorders</article-title>. <source/>Curr Opin Psychiatry
<year>2006</year>; <volume>19</volume>: <fpage>25</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">16612175</pub-id></mixed-citation>
</ref>
<ref id="bibr179-2040622320905215">
<label>179</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shah</surname><given-names>PJ</given-names></name><name><surname>Ebmeier</surname><given-names>KP</given-names></name><name><surname>Glabus</surname><given-names>MF</given-names></name></person-group>, <etal>et al</etal>
<article-title>Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study</article-title>. <source/>Br J Psychiatry
<year>1998</year>; <volume>172</volume>: <fpage>527</fpage>–<lpage>532</lpage>.<pub-id pub-id-type="pmid">9828995</pub-id></mixed-citation>
</ref>
<ref id="bibr180-2040622320905215">
<label>180</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sheline</surname><given-names>YI.</given-names></name></person-group>
<article-title>Neuroimaging studies of mood disorder effects on the brain</article-title>. <source/>Biol Psychiatry
<year>2003</year>; <volume>54</volume>: <fpage>338</fpage>–<lpage>352</lpage>.<pub-id pub-id-type="pmid">12893109</pub-id></mixed-citation>
</ref>
<ref id="bibr181-2040622320905215">
<label>181</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Posener</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Price</surname><given-names>JL</given-names></name></person-group>, <etal>et al</etal>
<article-title>High-dimensional mapping of the hippocampus in depression</article-title>. <source/>Am J Psychiatry
<year>2003</year>; <volume>160</volume>: <fpage>83</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="pmid">12505805</pub-id></mixed-citation>
</ref>
<ref id="bibr182-2040622320905215">
<label>182</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hebert</surname><given-names>M</given-names></name><name><surname>Merette</surname><given-names>C</given-names></name><name><surname>Paccalet</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>
<article-title>Electroretinographic anomalies in medicated and drug free patients with major depression: tagging the developmental roots of major psychiatric disorders</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry
<year>2017</year>; <volume>75</volume>: <fpage>10</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">28007463</pub-id></mixed-citation>
</ref>
<ref id="bibr183-2040622320905215">
<label>183</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fornaro</surname><given-names>M</given-names></name><name><surname>Bandini</surname><given-names>F</given-names></name><name><surname>Ogliastro</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Electroretinographic assessment in major depressed patients receiving duloxetine: might differences between responders and non-responders indicate a differential biological background?</article-title>
<source/>J Affect Disord
<year>2011</year>; <volume>135</volume>: <fpage>154</fpage>–<lpage>159</lpage>.<pub-id pub-id-type="pmid">21820182</pub-id></mixed-citation>
</ref>
<ref id="bibr184-2040622320905215">
<label>184</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bubl</surname><given-names>E</given-names></name><name><surname>Kern</surname><given-names>E</given-names></name><name><surname>Ebert</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>Seeing gray when feeling blue? Depression can be measured in the eye of the diseased</article-title>. <source/>Biol Psychiatry
<year>2010</year>; <volume>68</volume>: <fpage>205</fpage>–<lpage>208</lpage>.<pub-id pub-id-type="pmid">20359698</pub-id></mixed-citation>
</ref>
<ref id="bibr185-2040622320905215">
<label>185</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bubl</surname><given-names>E</given-names></name><name><surname>Ebert</surname><given-names>D</given-names></name><name><surname>Kern</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>
<article-title>Effect of antidepressive therapy on retinal contrast processing in depressive disorder</article-title>. <source/>Br J Psychiatry
<year>2012</year>; <volume>201</volume>: <fpage>151</fpage>–<lpage>158</lpage>.<pub-id pub-id-type="pmid">22700080</pub-id></mixed-citation>
</ref>
<ref id="bibr186-2040622320905215">
<label>186</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anda</surname><given-names>R</given-names></name><name><surname>Williamson</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults</article-title>. <source/>Epidemiology
<year>1993</year>; <volume>4</volume>: <fpage>285</fpage>–<lpage>294</lpage>.<pub-id pub-id-type="pmid">8347738</pub-id></mixed-citation>
</ref>
<ref id="bibr187-2040622320905215">
<label>187</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ford</surname><given-names>DE</given-names></name><name><surname>Mead</surname><given-names>LA</given-names></name><name><surname>Chang</surname><given-names>PP</given-names></name></person-group>, <etal>et al</etal>
<article-title>Depression is a risk factor for coronary artery disease in men: the precursors study</article-title>. <source/>Arch Intern Med
<year>1998</year>; <volume>158</volume>: <fpage>1422</fpage>–<lpage>1426</lpage>.<pub-id pub-id-type="pmid">9665350</pub-id></mixed-citation>
</ref>
<ref id="bibr188-2040622320905215">
<label>188</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pratt</surname><given-names>LA</given-names></name><name><surname>Ford</surname><given-names>DE</given-names></name><name><surname>Crum</surname><given-names>RM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up</article-title>. <source/>Circulation
<year>1996</year>; <volume>94</volume>: <fpage>3123</fpage>–<lpage>3129</lpage>.<pub-id pub-id-type="pmid">8989119</pub-id></mixed-citation>
</ref>
<ref id="bibr189-2040622320905215">
<label>189</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Glassman</surname><given-names>AH</given-names></name><name><surname>Shapiro</surname><given-names>PA.</given-names></name></person-group>
<article-title>Depression and the course of coronary artery disease</article-title>. <source/>Am J Psychiatry
<year>1998</year>; <volume>155</volume>: <fpage>4</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">9433332</pub-id></mixed-citation>
</ref>
<ref id="bibr190-2040622320905215">
<label>190</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nemeroff</surname><given-names>CB</given-names></name><name><surname>Goldschmidt-Clermont</surname><given-names>PJ.</given-names></name></person-group>
<article-title>Heartache and heartbreak–the link between depression and cardiovascular disease</article-title>. <source/>Nat Rev Cardiol
<year>2012</year>; <volume>9</volume>: <fpage>526</fpage>–<lpage>539</lpage>.<pub-id pub-id-type="pmid">22733213</pub-id></mixed-citation>
</ref>
<ref id="bibr191-2040622320905215">
<label>191</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Suls</surname><given-names>J</given-names></name><name><surname>Bunde</surname><given-names>J.</given-names></name></person-group>
<article-title>Anger, anxiety, and depression as risk factors for cardiovascular disease: the problems and implications of overlapping affective dispositions</article-title>. <source/>Psychol Bull
<year>2005</year>; <volume>131</volume>: <fpage>260</fpage>–<lpage>300</lpage>.<pub-id pub-id-type="pmid">15740422</pub-id></mixed-citation>
</ref>
<ref id="bibr192-2040622320905215">
<label>192</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jakobsen</surname><given-names>AH</given-names></name><name><surname>Foldager</surname><given-names>L</given-names></name><name><surname>Parker</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>Quantifying links between acute myocardial infarction and depression, anxiety and schizophrenia using case register databases</article-title>. <source/>J Affect Disord
<year>2008</year>; <volume>109</volume>: <fpage>177</fpage>–<lpage>181</lpage>.<pub-id pub-id-type="pmid">18053581</pub-id></mixed-citation>
</ref>
<ref id="bibr193-2040622320905215">
<label>193</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meier</surname><given-names>MH</given-names></name><name><surname>Gillespie</surname><given-names>NA</given-names></name><name><surname>Hansell</surname><given-names>NK</given-names></name></person-group>, <etal>et al</etal>
<article-title>Associations between depression and anxiety symptoms and retinal vessel caliber in adolescents and young adults</article-title>. <source/>Psychosom Med
<year>2014</year>; <volume>76</volume>: <fpage>732</fpage>–<lpage>738</lpage>.<pub-id pub-id-type="pmid">25373892</pub-id></mixed-citation>
</ref>
<ref id="bibr194-2040622320905215">
<label>194</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalenderoglu</surname><given-names>A</given-names></name><name><surname>Celik</surname><given-names>M</given-names></name><name><surname>Sevgi-Karadag</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Optic coherence tomography shows inflammation and degeneration in major depressive disorder patients correlated with disease severity</article-title>. <source/>J Affect Disord
<year>2016</year>; <volume>204</volume>: <fpage>159</fpage>–<lpage>165</lpage>.<pub-id pub-id-type="pmid">27344626</pub-id></mixed-citation>
</ref>
<ref id="bibr195-2040622320905215">
<label>195</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schonfeldt-Lecuona</surname><given-names>C</given-names></name><name><surname>Schmidt</surname><given-names>A</given-names></name><name><surname>Kregel</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>
<article-title>Retinal changes in patients with major depressive disorder - A controlled optical coherence tomography study</article-title>. <source/>J Affect Disord
<year>2018</year>; <volume>227</volume>: <fpage>665</fpage>–<lpage>671</lpage>.<pub-id pub-id-type="pmid">29174740</pub-id></mixed-citation>
</ref>
<ref id="bibr196-2040622320905215">
<label>196</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>George</surname><given-names>MS</given-names></name><name><surname>Ketter</surname><given-names>TA</given-names></name><name><surname>Parekh</surname><given-names>PI</given-names></name></person-group>, <etal>et al</etal>
<article-title>Brain activity during transient sadness and happiness in healthy women</article-title>. <source/>Am J Psychiatry
<year>1995</year>; <volume>152</volume>: <fpage>341</fpage>–<lpage>351</lpage>.<pub-id pub-id-type="pmid">7864258</pub-id></mixed-citation>
</ref>
<ref id="bibr197-2040622320905215">
<label>197</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pardo</surname><given-names>JV</given-names></name><name><surname>Pardo</surname><given-names>PJ</given-names></name><name><surname>Raichle</surname><given-names>ME.</given-names></name></person-group>
<article-title>Neural correlates of self-induced dysphoria</article-title>. <source/>Am J Psychiatry
<year>1993</year>; <volume>150</volume>: <fpage>713</fpage>–<lpage>719</lpage>.<pub-id pub-id-type="pmid">8480815</pub-id></mixed-citation>
</ref>
<ref id="bibr198-2040622320905215">
<label>198</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baxter</surname><given-names>LR</given-names><suffix>Jr</suffix></name><name><surname>Schwartz</surname><given-names>JM</given-names></name><name><surname>Phelps</surname><given-names>ME</given-names></name></person-group>, <etal>et al</etal>
<article-title>Reduction of prefrontal cortex glucose metabolism common to three types of depression</article-title>. <source/>Arch Gen Psychiatry
<year>1989</year>; <volume>46</volume>: <fpage>243</fpage>–<lpage>250</lpage>.<pub-id pub-id-type="pmid">2784046</pub-id></mixed-citation>
</ref>
<ref id="bibr199-2040622320905215">
<label>199</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bench</surname><given-names>CJ</given-names></name><name><surname>Friston</surname><given-names>KJ</given-names></name><name><surname>Brown</surname><given-names>RG</given-names></name></person-group>, <etal>et al</etal>
<article-title>Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions</article-title>. <source/>Psychol Med
<year>1993</year>; <volume>23</volume>: <fpage>579</fpage>–<lpage>590</lpage>.<pub-id pub-id-type="pmid">7901863</pub-id></mixed-citation>
</ref>
<ref id="bibr200-2040622320905215">
<label>200</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kimbrell</surname><given-names>TA</given-names></name><name><surname>Little</surname><given-names>JT</given-names></name><name><surname>Dunn</surname><given-names>RT</given-names></name></person-group>, <etal>et al</etal>
<article-title>Frequency dependence of antidepressant response to left prefrontal repetitive transcranial magnetic stimulation (rTMS) as a function of baseline cerebral glucose metabolism</article-title>. <source/>Biol Psychiatry
<year>1999</year>; <volume>46</volume>: <fpage>1603</fpage>–<lpage>1613</lpage>.<pub-id pub-id-type="pmid">10624541</pub-id></mixed-citation>
</ref>
<ref id="bibr201-2040622320905215">
<label>201</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martinot</surname><given-names>JL</given-names></name><name><surname>Hardy</surname><given-names>P</given-names></name><name><surname>Feline</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Left prefrontal glucose hypometabolism in the depressed state: a confirmation</article-title>. <source/>Am J Psychiatry
<year>1990</year>; <volume>147</volume>: <fpage>1313</fpage>–<lpage>1317</lpage>.<pub-id pub-id-type="pmid">2399999</pub-id></mixed-citation>
</ref>
<ref id="bibr202-2040622320905215">
<label>202</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ashraf</surname><given-names>H</given-names></name><name><surname>Nowroozzadeh</surname><given-names>MH.</given-names></name></person-group>
<article-title>Diurnal variation of retinal thickness in healthy subjects</article-title>. <source/>Optom Vis Sci
<year>2014</year>; <volume>91</volume>: <fpage>615</fpage>–<lpage>623</lpage>.<pub-id pub-id-type="pmid">24811843</pub-id></mixed-citation>
</ref>
<ref id="bibr203-2040622320905215">
<label>203</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Read</surname><given-names>SA</given-names></name><name><surname>Collins</surname><given-names>MJ</given-names></name><name><surname>Alonso-Caneiro</surname><given-names>D.</given-names></name></person-group>
<article-title>Diurnal variation of retinal thickness with spectral domain OCT</article-title>. <source/>Optom Vis Sci
<year>2012</year>; <volume>89</volume>: <fpage>611</fpage>–<lpage>619</lpage>.<pub-id pub-id-type="pmid">22446718</pub-id></mixed-citation>
</ref>
<ref id="bibr204-2040622320905215">
<label>204</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jo</surname><given-names>YJ</given-names></name><name><surname>Heo</surname><given-names>DW</given-names></name><name><surname>Shin</surname><given-names>YI</given-names></name></person-group>, <etal>et al</etal>
<article-title>Diurnal variation of retina thickness measured with time domain and spectral domain optical coherence tomography in healthy subjects</article-title>. <source/>Invest Ophthalmol Vis Sci
<year>2011</year>; <volume>52</volume>: <fpage>6497</fpage>–<lpage>6500</lpage>.<pub-id pub-id-type="pmid">21705686</pub-id></mixed-citation>
</ref>
<ref id="bibr205-2040622320905215">
<label>205</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferro Desideri</surname><given-names>L</given-names></name><name><surname>Barra</surname><given-names>F</given-names></name><name><surname>Skhiri</surname><given-names>MI</given-names></name></person-group>, <etal>et al</etal>
<article-title>Methodological concerns on retinal thickness evaluation by spectral domain optical coherence tomography in patients with major depressive disorder</article-title>. <source/>J Affect Disord
<year>2018</year>; <volume>238</volume>: <fpage>226</fpage>–<lpage>227</lpage>.<pub-id pub-id-type="pmid">29886203</pub-id></mixed-citation>
</ref>
<ref id="bibr206-2040622320905215">
<label>206</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hamon</surname><given-names>M</given-names></name><name><surname>Blier</surname><given-names>P.</given-names></name></person-group>
<article-title>Monoamine neurocircuitry in depression and strategies for new treatments</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry
<year>2013</year>; <volume>45</volume>: <fpage>54</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">23602950</pub-id></mixed-citation>
</ref>
<ref id="bibr207-2040622320905215">
<label>207</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>aan het Rot</surname><given-names>M</given-names></name><name><surname>Mathew</surname><given-names>SJ</given-names></name><name><surname>Charney</surname><given-names>DS</given-names></name></person-group>
<article-title>Neurobiological mechanisms in major depressive disorder</article-title>. <source/>CMAJ
<year>2009</year>; <volume>180</volume>: <fpage>305</fpage>–<lpage>313</lpage>.<pub-id pub-id-type="pmid">19188629</pub-id></mixed-citation>
</ref>
<ref id="bibr208-2040622320905215">
<label>208</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thase</surname><given-names>ME.</given-names></name></person-group>
<article-title>Molecules that mediate mood</article-title>. <source/>N Engl J Med
<year>2007</year>; <volume>357</volume>: <fpage>2400</fpage>–<lpage>2402</lpage>.<pub-id pub-id-type="pmid">18057345</pub-id></mixed-citation>
</ref>
<ref id="bibr209-2040622320905215">
<label>209</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tian</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>XH</given-names></name><name><surname>Liu</surname><given-names>YH.</given-names></name></person-group>
<article-title>Potential role of retina as a biomarker for progression of Parkinson’s disease</article-title>. <source/>Int J Ophthalmol
<year>2011</year>; <volume>4</volume>: <fpage>433</fpage>–<lpage>438</lpage>.<pub-id pub-id-type="pmid">22553695</pub-id></mixed-citation>
</ref>
<ref id="bibr210-2040622320905215">
<label>210</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salas</surname><given-names>M</given-names></name><name><surname>Drexler</surname><given-names>W</given-names></name><name><surname>Levecq</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>
<article-title>Multi-modal adaptive optics system including fundus photography and optical coherence tomography for the clinical setting</article-title>. <source/>Biomed Opt Express
<year>2016</year>; <volume>7</volume>: <fpage>1783</fpage>–<lpage>1796</lpage>.<pub-id pub-id-type="pmid">27231621</pub-id></mixed-citation>
</ref>
<ref id="bibr211-2040622320905215">
<label>211</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brandt</surname><given-names>AU</given-names></name><name><surname>Oberwahrenbrock</surname><given-names>T</given-names></name><name><surname>Mikolajczak</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Visual dysfunction, but not retinal thinning, following anti-NMDA receptor encephalitis</article-title>. <source/>Neurol Neuroimmunol Neuroinflamm
<year>2016</year>; <volume>3</volume>: <fpage>e198</fpage>.<pub-id pub-id-type="pmid">26894203</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>